



EirGenix, Inc.
2021 Annual Shareholders' Meeting Minutes
(Translation)

Time and Date: 9:30 a.m., August 3, 2021

Place: ACE Biotek (No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County)

Total outstanding shares: 208,038,856 shares

**Total shares represented by shareholders present in person or by proxy:
113,361,116 shares**

**Percentage of shares held by shareholders present in person or by proxy:
54.49%**

**Directors present: Formosa Laboratories, Inc., Representative: Cheng-Yu
Cheng; National Development Fund, Executive Yuan, Representative:
Jing-Jer Lin; Taiwan Capital Buffalo II Bioventures, LP,
Representative: I-Ta Lu; Lee-Cheng Liu; Ming-Thaur Chang**

Chairman: Augusta Inc., Representative: Chung-Hur Lee

Recorder: Ya-Han Liu

**The aggregate shareholding of the shareholders present in person or by
proxy constituted a quorum. The Chairman called the meeting to order.**

I. Chairman Remarks(omitted)

II. Report Items:

Item No.1

Subject: Report the business results of 2020.

Explanatory Notes: Please refer to Attachment I.

Item No.2

Subject: Audit Committee's review report.

Explanatory Notes: Please refer to Attachment II.

Item No.3

Subject: Report Accumulated Losses Reaching One-Half of Paid-in Capital and Execution of the Improvement Plan of Business Operations for the Fourth Quarter of 2020.

Explanatory Notes:

For the Execution of the Improvement Plan of Business Operations for the Fourth Quarter of 2020, please refer to Attachment III.

Item No.4

Subject: Report the Status of the 1st Domestic Secured Convertible Corporate Bonds.

Explanatory Notes:

According to Article 246 of Company Act, the Status of the 1st Domestic Secured Convertible Corporate Bonds, please refer to Attachment IV.

Item No.5

Subject: Amendment to the Rule of Corporate Social Responsibility Best Practice Principles.

Explanatory Notes:

Amend the Rule of Corporate Social Responsibility Best Practice Principles to cooperate with EirGenix's corporate governance planning. For a comparison table of the Rule of Corporate Social Responsibility Best Practice Principles, please refer to Attachment V.

Item No.6

Subject: Amendment to the Rule of Ethical Corporate Management Best Practice Principles and Procedures for Ethical Management and Guidelines for Conduct.

Explanatory Notes:

Amend the Rule of Ethical Corporate Management Best Practice Principles and Procedures for Ethical Management and Guidelines for Conduct to cooperate with EirGenix's corporate governance planning. For a comparison table of the Rule of Ethical Corporate Management Best Practice Principles and Procedures for Ethical Management and Guidelines for Conduct, please refer to Attachment VI and VII.

III. Proposed Resolutions

Item No.1 (Proposed by the Board of Directors)

Subject: Accept 2020 Financial Statements and the Business Report.

Explanatory Notes:

1. EirGenix's 2020 Financial Statements, including Balance Sheets, Statements of Comprehensive Income, Statements of Changes in Equity, and Statements of Cash Flows, were audited by independent auditors, Ms. Shu-Fen Yu and Mr. Sheng-Wei Teng, of PricewaterhouseCoopers Taiwan.
2. 2020 Business Report, Independent Auditors' Report, and the aforementioned Financial Statements are attached hereto as Attachments I, II and VIII.

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 111,603,013 votes (4,697,660 votes)	98.44%
Votes against: 185,372 votes (185,372 votes)	0.16%
Votes invalid: 0 vote	0.00%



Votes abstained: 1,572,731 votes (1,564,731 votes)	1.38%
---	-------

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Item No.2 (Proposed by the Board of Directors)

Subject: Ratification of the 2020 Deficit Offset Proposal.

Explanatory Notes:

EirGenix's 2020 financial statement showed an accumulated deficit is NT\$2,930,918,673. According to Company's Articles of Incorporation, EirGenix does not intend to distribute dividends and bonuses this year. Please refer to the 2020 Deficit Offset Statement below.

EirGenix, Inc.

2020 Deficit Offset Statement

	In NTD
Undistributed Earnings in the beginning of the year	(1,889,249,356)
2020 Net loss after tax	<u>(1,041,669,317)</u>
Deficit to be offset at the end of the year	<u>(2,930,918,673)</u>

Chairman: Chung-Hur Lee Officer: Lee-Cheng Liu Head of the Accounting Dept.: Hsiu-Chuan Yang

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 111,594,313 votes (4,681,960 votes)	98.44%
Votes against: 205,672 votes (205,672 votes)	0.18%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,561,131 votes (1,560,131 votes)	1.37%



*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

IV. Items for Discussion

Item No.1 (Proposed by the Board of Directors)

Subject: Amendment to the Company's Articles of Incorporation.

Explanatory Notes:

It is proposed to amend EirGenix's Articles of Incorporation based on EirGenix's operation planning. The Comparison Table for the Company's Articles of Incorporation is attached hereto as Attachment IX.

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 111,608,562 votes (4,696,209 votes)	98.45%
Votes against: 209,372 votes (209,372 votes)	0.18%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,543,182 votes (1,542,182 votes)	1.36%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Item No.2 (Proposed by the Board of Directors)

Subject: Amendment to the Rules of Procedure for Shareholder Meetings.

Explanatory Notes:

1. It is proposed to amend the Company's Rules of Procedure for Shareholder Meetings pursuant to the official announcement from Taipei Exchange dated on June 12, 2020

(official letter No.10900582662) and February 9, 2021 (official letter No. 11000519042).

2. For a comparison table of the Rules of Procedure for Shareholder Meetings is attached hereto as Attachment X.

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 111,590,452 votes (4,678,099 votes)	98.43%
Votes against: 210,372 votes (210,372 votes)	0.18%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,560,292 votes (1,559,292 votes)	1.37%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Item No.3 (Proposed by the Board of Directors)

Subject: Amendment to the Regulations Governing Procedure for Election of Directors.

Explanatory Notes:

1. It is proposed to amend the Company's Regulations Governing Procedure for Election of Directors pursuant to the official announcement from Taipei Exchange dated on June 12, 2020 (official letter No.10900582662).
2. For a comparison table of the Regulations Governing Procedure for Election of Directors is attached hereto as Attachment XI.

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented
----------------	----------------------------

	share present
Votes in favor: 111,597,462 votes (4,685,109 votes)	98.44%
Votes against: 213,372 votes (213,372 votes)	0.18%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,550,282 votes (1,549,282 votes)	1.36%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Item No.4 (Proposed by the Board of Directors)

Subject: Proposal to Release the Prohibition on Directors or Representatives of Directors from Participation in Competitive Business.

Explanatory Notes:

1. According to Article 209 of Company Act, “A director who does anything for himself or on behalf of another person that is within the scope of the company's business, shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.”
2. It is proposed that the shareholders meeting agree to release the prohibition on directors or representatives of directors from participation in competitive business as follows:

Name of Director/Representative	Added concurrent positions within the company's business scope
National Development Fund, Executive Yuan	Director of Alar Pharmaceuticals Inc. Director of Point Robotics MedTech Inc.
Taiwania Capital Buffalo II Bioventures, LP	Director of Point Robotics MedTech Inc.

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 111,436,593 votes (4,524,240 votes)	98.30%

Votes against: 299,737 votes (299,737 votes)	0.26%
Votes invalid: 0 vote	0.00%
Votes abstained: 1,624,786 votes (1,623,786 votes)	1.43%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Item No.5 (Proposed by the Board of Directors)

Subject: Adoption of the Issuance of Employee Restricted Stock Awards.

Explanatory Notes:

Regulations of 1st Employee Restricted Stock in 2021

1. To attract and retain the professional talents required by EirGenix, to enhance the coherence of employees, and to create the benefits of EirGenix and its shareholders, EirGenix intends to issue total 1,000,000 shares at NT\$10 per share and total amount is NT\$10,000,000, pursuant to Section 8 of Article 267 of the Company Act and related rules, including the Regulations Governing the Offering and Issuance of Securities by Securities Issuers to lay down the Regulations of 1st Employee Restricted Stocks in 2021.
2. The content and items of the Restricted Employee Stock are as follow:
 - (1) Issue Price: NT\$0 per share.
 - (2) The Eligibility of Employee: All regular employees employed in the company and controlling and subordinate company domestic and abroad on the date of issuance of the Restricted Employee Stock are eligible for the subscription of Restricted Employee Stock. The term "controlling and subordinate company" is recognized in accordance with the standards of Article 369-2, Article 369-3, Article 369-9, Paragraph 2 and Article 369-11 of the Company Act.
 - (3) Condition of Vesting: After subscription, the employee must achieve to conditions below. During the vesting period, any resignation, suspension, resignation, dismissal, retirement, transfer to a related company, etc., will be regarded as non-continuous employment.

Condition A: Company operation performance and employee personal KPI

Achieve a positive income before tax for 3 quarters, and employee personal average KPI shall be over 2.66 for three consecutive years. 33.3% of total shares will be released

Condition B: Employee job tenure and employee personal KPI

Work in EirGenix for ten years, and employee personal average KPI shall be over 2.66 for three consecutive years. 16.7% of total shares will be released

Condition C: Development of biosimilar EG12014 and employee personal KPI

Timing I: Complete EG12014 Phase 3 and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.

Timing II: EG12014 Launched to market and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.

Condition D: Development of biosimilar EG1206A and employee personal KPI

Timing I: Complete EG1206A Phase 1 and employee personal average KPI shall be over 2.66 for three consecutive years. 5.6% of total shares will be released

Timing II: Complete EG1206A out-licensing or Phase 3 and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released

Condition E: New plant in Zhubei start running and complete 1,000L or 2*2,000L scale process validation and employee personal KPI

The new plant in Zhubei starts running, and complete 1000L or 2*2000L scale process validation and employee personal average KPI shall be over 2.66 for three consecutive years. 11.1% of total shares will be released.

- (4) Category of Restricted Employee Stock: Common shares of the company.
- (5) Measures to be taken when employees fail to achieve the vesting conditions or in the event of inheritance: The Company will redeem the

issued restricted stock awards and cancel the full number of the shares. For dividends and dividends that have been distributed, employees do not need to return or pay back. When subscribers are disabled or die due to occupational disasters, the restricted employee stock that do not meet the vesting conditions, the company will withdraw their shares and cancel their shares in accordance with the law. However, if the employee has made outstanding contributions to the company, loyalty and due diligence and other special circumstances, and those approved by the board of directors are not including in this limitation, then the board of directors shall be authorized to deal with the restricted employee stocks that do not meet the vesting conditions.

(6) Number of Restricted Employee Stock eligible for subscription: The number for subscription to respective employee is determined on the job title, level, salary, job tenure, performance, contribution of company's major operation goals, the regulations at the subscription time and other caused as the reference.

(7) Restricted rights before employees meet the vesting conditions:

- A. During the vesting period, the employee may not sell, pledge, transfer, give to another person, create any encumbrance on, or otherwise dispose of, restricted stock awards
- B. Voting right in Shareholders' Meeting: The same as common stock.
- C. Dividend: The same as common stock.

3. Expected expense amount: The calculation of the expected expense amount is based on EirGenix 's outstanding shares 243,038,856 shares, estimate issue 1,340,000 shares by restricted stock, and the average closing price in April 2021 is NT\$144.13 as fair value. The expected expenses amount is NT\$144.13 per share. If all employees achieve the condition, then the total estimated expense amount is NT\$144,130,000. Based on the estimated issue date and given date are one to eleven years, the annual amortized expense from 2021 to 2031 respectively will be NT\$20,325,000、NT\$40,649,000、NT\$40,649,000、NT\$23,306,000、NT\$5,962,000、NT\$2,407,000、NT\$2,407,000、NT\$2,407,000、NT\$2,407,000、NT\$2,407,000 and NT\$1,203,000. However, the actual amount will be calculated by the fair value on given date and recognize related expenses in installments during the vested period.

4. Dilution of EPS and other factors affecting shareholders' equity: EirGenix issues Restricted Employee Stock, representing 0.41% of an aggregate number of all shares issued by EirGenix this time, dilution to EPS from 2021 to 2031 respectively will be NT\$0.083、NT\$0.166、NT\$0.166、NT\$0.095、NT\$0.024、NT\$0.01、NT\$0.01、NT\$0.01、NT\$0.01、NT\$0.01 and NT\$0.005. Accordingly, this will not result in a material impact on the shareholder's equity.
5. Other important stipulations: The Employee Restricted Stock issued may be deposited in a security trust account.
6. It is proposed to the shareholders' meeting to authorize the board of directors to adjust the condition or regulation of the Employee Restricted Stock this time by law or as required by competent authority and to also authorize the board of directors to decide the actual list of subscribers and the amount. Without violating the principle of content agreed by the shareholders meeting, the board of directors shall have full power to handle the issue.

Regulations of 2nd Employee Restricted Stock in 2021

1. To attract, and retain the professional talents required by EirGenix, to enhance the coherence of employees, and to create the benefits of EirGenix and its shareholders, EirGenix intends to issue total 340,000 shares at NT\$10 per share and total amount is NT\$3,400,000, pursuant to Section 8 of Article 267 of the Company Act and related rules, including the Regulations Governing the Offering and Issuance of Securities by Securities Issuers to lay down the Regulations of 2nd Employee Restricted Stocks in 2021.
2. The content and items of the Restricted Employee Stock are as follow:
 - (1) Issue Price: NT\$0 per share
 - (2) The Eligibility of Employee: All regular employees employed in the company and controlling and subordinate company domestic and abroad on the date of issuance of the Restricted Employee Stock are eligible for the subscription of Restricted Employee Stock. The term "controlling and subordinate company" is recognized in accordance with the standards of Article 369-2, Article 369-3, Article 369-9, Paragraph 2 and Article 369-11 of Company Act.
 - (3) Condition of Vesting: After subscription, the employee must achieve to

conditions below. During the vesting period, any resignation, suspension, resignation, dismissal, retirement, transfer to a related company, etc., will be regarded as non-continuous employment.

Condition A: Work in EirGenix for one years, and employee personal average KPI shall be over 2.5, half of the total shares will be released next year.

Condition B: EirGenix operation KPI shall be over 2.5, one third of the total shares will be released next year.

- (4) Category of Restricted Employee Stock: Common shares of the company.
 - (5) Measures to be taken when employees fail to achieve the vesting conditions or in the event of inheritance: The Company will redeem the issued restricted stock awards and cancel the full number of the shares. For dividends and dividends that have been distributed, employees do not need to return or pay back. When subscribers are disabled or die due to occupational disasters, the restricted employee stock that do not meet the vesting conditions, the company will withdraw their shares and cancel their shares in accordance with the law. However, if the employee has made outstanding contributions to the company, loyalty and due diligence and other special circumstances, and those approved by the board of directors are not including in this limitation, then the board of directors shall be authorized to deal with the restricted employee stocks which do not meet the vest conditions.
 - (6) Number of Restricted Employee Stock eligible for subscription: The number for subscription to respective employee is determined on the job title, level, salary, job tenure, performance, contribution of company's major operation goals, the regulations at the subscription time and other caused as the reference.
 - (7) Restricted rights before employees meet the vesting conditions:
 - A. During the vesting period, the employee may not sell, pledge, transfer, give to another person, create any encumbrance on, or otherwise dispose of, restricted stock awards
 - B. Voting right in Shareholders' Meeting: The same as common stock
 - C. Dividend: The same as common stock
3. Expected expense amount: The calculation of the expected expense amount is

based on EirGenix 's outstanding shares 243,038,856 shares, estimate issue 1,340,000 shares by restricted stock, and the average closing price in April 2021 is NT\$144.13 as fair value. The expected expenses amount is NT\$144.13 per share. If all employees achieve the condition, the total estimated expense is NT\$49,004,000. Based on the estimate issue date and given date are one to two years, the annual amortized expense from 2021 to 2022 will be NT\$40,356,000 and NT\$8,648,000, respectively.

However, the actual expenses will be calculated by the fair value on given date and recognize related expenses in installments during the vested period.

4. Dilution of EPS and other factors affecting shareholders' equity: EirGenix issues Restricted Employee Stock, representing 0.14% of an aggregate number of all shares issued by EirGenix this time, dilution to EPS from 2021 to 2022 will be NT\$0.165, NT\$0.035, respectively. Accordingly, this will not result in a material impact on the shareholder's equity.
5. Other important stipulations: The Employee Restricted Stock issued may be deposited in a security trust account.
6. It is proposed to the shareholders' meeting to authorize the board of directors to adjust the condition or regulation of the Employee Restricted Stock this time by law or competent authority required. Also authorize the board of directors to decide the actual list of subscribers and the amount. Without violating the principle of content agreed by the shareholders meeting, the board of directors shall have full power to handle the issue.

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 97,877,277 votes (4,528,811 votes)	86.34%
Votes against: 371,112 votes (371,112 votes)	0.32%
Votes invalid: 0 vote	0.00%
Votes abstained: 15,112,727 votes (1,547,840 votes)	13.33%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Item No.6 (Proposed by the Board of Directors)

Subject: Approval of Private Placement of Securities.

Explanatory Notes:

1. EirGenix has considered the timeliness of financing activities and the operational needs, and it will conduct private placements of common shares at a proper time depending on the capital market. The maximum number of total shares issued will be 55,000,000 shares. It will be issued from one to four closings within one year of a resolution adopted by a shareholders meeting to increase the flexibility of EirGenix's financing activities. The anticipated issuance information is as follows. The actual issuance limit will be submitted to the shareholders meeting to authorize the board of directors to determine it based on market condition and the result of negotiations with investors.

Anticipated number of closings	Anticipated number of shares	It is estimated to conduct private placements for capital increase in four closings. The unissued number of shares may be combined with the next closing, or the anticipated number of shares of each closing may be combined together. Total number of shares issued shall not exceed 55,000,000 shares.
First time	20,000,000	
Second time	15,000,000	
Third time	10,000,000	
Fourth time	10,000,000	

2. The issuance of private placements is conducted in accordance with the "Securities and Exchange Act" and "Directions for Public Companies Conducting Private Placements of Securities".
3. The basis and reasonableness of the private placement pricing:
Reference price is the simple average closing price of the common shares of the TWSE listed or TPEX listed company for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction; or the simple average closing price of the common shares of the TWSE listed or TPEX listed

company for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction. The price shall be the higher of the above two calculations. The private placement pricing shall not be lower than 50% of the reference price. The percentage is based on a reasonable private placement pricing statement issued by an independent expert. Please refer to Attachment XII. The private placement price, as well as the 2020 issue price of the secondary public offering, are tentatively set at NT\$91.5 per share. The actual price will be determined by submission to the shareholders meeting to authorize the board of directors depending on the market condition.

4. Source and total amount of the private placement: In accordance with Article 43-6 of the Securities Exchange Act, the total estimated amount of the private placement is NT\$5,032,500,000.
5. The method for selecting the specific persons and the anticipated benefits:
 - (1) The placees of the private placement are strategic investors. In accordance with the Article 43-6 of the Securities and Exchange Act and Taiwan Finance Certificate (1) No. 0910003455 issued by the Financial Supervisory Commission on June 13, 2002, it states to select those who are beneficial to the long-term development of the Company, and improve the operational performance, strengthen competitiveness, and generate benefits for existing shareholders' equity.
 - (2) The method and purpose for selecting the placees: the purpose for the placees selected this time is to introduce strategic investors. The main targets are strategic investors who have developing experiences in biomedicine and health and can stabilize the Company's equity and capital structure.
 - (3) The necessity of the placees: to accelerate the product developing efficiency as well as the process of the same drug series to complete the production line. By the comprehensive effect of expanding the market, it can establish EirGenix's unique status in the international biosimilars and CDMO field. In order to sustain EirGenix's operation and development, it is necessary to conduct private placement to introduce strategic investors by resolution.

(4) EirGenix has signed the letter of intention of the private placement with Hong Wei Investment Co., Ltd. on April 6, 2021. A total of 55,000,000 common shares issued by private placement will be subscribed by Hong Wei Investment Co., Ltd. or a designated third party at the price of NT\$91.5. The aforementioned investor will have 18.56% shareholding of EirGenix and become the first majority shareholder after subscription. The major management team of Hong Wei Investment Co., Ltd. is the founder of Foxconn Technology Group and YongLin Education Foundation, Mr. Kuo Tai-Ming and his team. He is very positive about the strategic direction and operational performance of EirGenix 's research and development ability, production and mass production technologies in the biotechnology industry.

(5) Hong Wei Investment Co., Ltd. is not a related party of EirGenix.

(6) There is no significant change in managerial control within the 1 year period immediately preceding the day on which the board of directors resolves on the private placement, and no significant change in managerial control after the introduction of strategic investors through private placement

(7) Information on the majority shareholder of the Hong Wei Investment Co., Ltd.:

Shareholder	Shareholding %	Relation with EirGenix, Inc.
Hong Han Investing Co., Ltd.	100%	None

(8) Anticipated benefits: improve EirGenix's operating scale, horizontal and vertical integration, and product or market development collaboration, assist EirGenix to improve technology, efficiency, expand the operational scale, and improve the market status. It has positive benefits in creating EirGenix and shareholder value.

6. The reasons for the necessity of conducting the private placement:

(1) The reasons for not using a public offering:

With the considerations of the timeliness of financing activities and the uncertainty of the capital market, and the benefit for the Company's long term operating development because of the transfer limit of the private placement common share, it plans to conduct the financial activities with

private placement.

(2) The use of the funds for each closing of the private placement, and the anticipated benefits:

- A. The use of the funds for each closing of the private placement of common shares is to replenish operating capital for research and development expenses, plant expansion, horizontal and vertical integration, and other operational funding needs. It could strengthen EirGenix's financial structures and promote stable growth in operation.
- B. Anticipated benefits: each closing is to act in concert with EirGenix's long-term development. It can cope with the product development needs and expand operational scales to strengthen EirGenix's financial structure.

7. The rights and obligations of the private placement of common share is technically the same as the issued share. However, in accordance with the Securities and Exchange Act, the private placement of common shares may not be resold within three years after the delivery date except for the transfer objects in accordance with the Article 43-8 of the Securities and Exchange Act. The private placement of common shares may be submitted to the shareholders meeting to authorize the board of directors to file an application to the Competent Authority with relevant regulations for supplemental public issuance and listed transactions depending on the condition after three years of the delivery date and meet certain conditions of the competent authority.
8. The main content of the private placement plan, except with the actual issuance price, includes number of shares for issuance, terms of issuance, period for payment of subscription, record date of capital increase, planned item, estimated progress, estimated possible benefits, and all other matters related to the issuance plan. It is proposed to the shareholders meeting to authorize the board of directors to adjust, establish, and handle according to market conditions. Any changes in the future due to changes in law and regulation, amendment instructed by the competent authority, and changes based on operational evaluation or objective circumstance, shall be proposed to the shareholders meeting to authorize the board of directors to take full

charge of it.

9. According to Article 43-6 of the Securities and Exchange Act, the explanation of Company's private placement of security resolutions can be found on the Market Observation Post System (<https://mops.twse.com.tw>) and EirGenix website (<http://www.eirgenix.com>).

Voting Results:

Shares represented at the time of voting: 113,361,116

Voting Results	% of the total represented share present
Votes in favor: 97,893,702 votes (4,545,236 votes)	86.35%
Votes against: 362,096 votes (362,096 votes)	0.31%
Votes invalid: 0 vote	0.00%
Votes abstained: 15,105,318 votes (1,540,431 votes)	13.32%

*Including votes casted electronically (number in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

Summary of shareholders' statement:

Shareholder No. 867:

According to the explanation in the meeting agenda, private placement can improve the company's business, and there is no significant change in managerial control in the future; the private placement pricing shall not be lower than 50% of the reference price. The private placement price may affect the shareholders' original rights and interests, whether the company tries to set a higher price to protect shareholders' rights and interests. Please record this statement and the response in the meeting minutes.

The Chairman and the person designated by the Chairman responded to the above statements:

Response by CEO Lee-Cheng Liu:

The tentative private placement price is the same as the price of the secondary public offering of 2020, which is set at NT\$91.5 per share. The private placement pricing shall



not be lower than 50% of the reference price; the final price will be based on the reference price with the discount ratio. The private placement of common shares can be filed through an application to the Competent Authority with relevant regulations for supplemental public issuance and listed transactions depending on meeting the specific profit condition after three years of the delivery date. This private placement can expand EirGenix's operating scale, accelerate product development, and boost the CDMO business by expanding production capacity. Therefore, as per the aforementioned explanations and the consideration of shareholders' rights and interests, setting the private placement price at NT\$91.5 per share is reasonable.

Response by Chairman Chung-Hur Lee:

Protecting shareholders' rights and interest is the most important thing to the management team. The priority of the company's operating decisions is to protect and enhance shareholders' rights and interests.

V. Extemporaneous Motions: None.

VI. Meeting Adjourned

EirGenix, Inc.**2020 Annual Business Report****1. 2020 Business Result****(1) Business plan implementing results**

EirGenix was established on December 21, 2012 and listed in the market on June 28, 2019. It is a biotechnology and medical company focusing on biosimilars, drug discovery, and biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The annual operating incomes of 2020 and 2019 are NT\$1,071,838 thousand dollars and 476,085 thousand dollars respectively with a 125% growth. The source of revenue in 2020 is the continued growth in CDMO business, the authorized contract with Sandoz on self-developed product EG12014, and step-by-step milestone payments recognition. EirGenix holds the critical technology of biotechnological drug development and manufacture and is able to provide differentiated services with high added-value. The consistent and stable operating income can cover part of the development expense for biosimilars. Various drug development projects are being implemented successively as planned. EirGenix's financial and business condition will rise substantially after obtaining the medicine certificate for mass production.

(2) Research and development status**I. Establish competitive and complete production line development strategies:**

- A. There are seven self-developed products including four biosimilars, one is the Her2 biosimilar with new formulation for subcutaneous injection, one antibody drug conjugate, and one carrier protein. In the current product pipeline, we applied an unique strategy of developing a Her2 franchise products to synergize future market penetration.
- B. The primary end point analysis of the phase 3 clinical trial of EG12014 (biosimilar of Roche Herceptin®, with indication of early breast cancer patients.) was completed on March 23rd, 2021, and shows the study has met its primary end-point. EG12014 has shown equivalent efficacy to Herceptin® in regard to its clinical response (pathologic complete response, pCR, defined as ypTO/is ypN0). After completing the interim clinical study report and all document required for eCDT, we plan to submit an application for medicinal products registration of BLA to FDA and MAA to EMA in the Q4 of 2021.
- C. On April 29th, 2019, EirGenix signed a global exclusive authorized sales contract,

except Taiwan and China, with Sandoz AG, a world well-known pharmaceutical factory for generic drugs and biosimilars. The licensing agreement includes a signing fee and milestone payments, and additional royalty income of product sales in the authorized markets after product launch. EirGenix is also responsible for the manufacture of EG12014 after launching in the market. Sandoz AG, a Novartis Division, is in the leading position in the global generic drug and biosimilars fields. They have a long history of 134 years and abundant drug development and sales experience in biosimilars and antineoplastic drugs. This strategic alliance will improve the global competitiveness therefore benefit to our CDMO business expansion. The launch of EG12014 would provide more treatment choices and opportunity for patients with HER2 breast cancer once the product launches in the market.

- D. The development of other products in the pipeline are in progress according to our plan. The Phase 1 pharmaceutical kinetic clinical study for EG1206A will be initiated in the early of 2022, and the IND for EG13074 will be submitted prior to the end of 2022.

II. Outstanding development and manufacture technology of biotechnological drugs:

- A. The operating income has been increasing by years due to consistent and stable growth of CDMO business. The CDMO business had reached the break-even point in 2016, and annual signed contract value had grown significantly since 2015
- B. The core competitiveness of EirGenix's CDMO business is owning two major production technologies: Mammalian cell culture development and Microbial strain fermentation development with professional capabilities of development, manufacture, and analysis. Through a vertical integration operating model, we can effectively keep track of the quality and cost control. Because the existing facility in Xizhi has reached its full capacity, a large scale commercial production facility that meets the requirement of international PIC/S GMP was built in Hsinchu Biomedical Science Park at the beginning of 2019. It is used for the self-developed biosimilars EG12014 future production needs in the market. It could also attract international and domestic clients with late developmental stage products which required large-scale production, and product commercial launches.
- C. In 2017, a Japanese customer transferred its production line from a Japanese CMO to EirGenix for a product that was already on the market. After completing the technology transfer and process validation, we submitted post approval change to Pharmaceuticals and Medical Devices Agency (PMDA), an independent administrative institution authorized by the Ministry of Health and Welfare, for

inspection in September 2019. The inspection went well with no major deficiency and received a PMDA approval letter on February 3, 2020. The customer started to transfer its production orders to us and began negotiation for long-term supply. After 9 months negotiation of supply agreement, EirGenix entered into an agreement for long-term supply on March 2, 2021 and became the first long-term biopharmaceutical factory for biological drugs in the Japanese market. The product is a necessary drug for cancer treatment with over 30% market share in the same category in Japan. It is the only biopharmaceutical factory in Taiwan and China, and one of a few Asian biopharmaceutical factories that was contracted by PMDA. With this accreditation, it would increase the willingness and confidence of Japanese and international biotechnology companies to contract manufacturing and enhance sales promotion. The market demand of Japanese biopharmaceuticals CDMO has been increasing in recent years. With the actual sales of this product in Japan, it will expand the competitive advantage in the Japanese market and significantly increase the willingness and confidence of Japanese and international biotechnology companies to entrust manufacturing. This major milestone will accelerate the sales growth of CDMO.

D. COVID-19 fast screening reagents and vaccines:

- (A) EirGenix also collaborates with Medigen Vaccine Biologics Corporation, a domestic vaccine manufacturer, and provides antigen protein production development and GMP mass production service. This is a warp speed development project for vaccine development and production. It required to develop the S-2P antigen protein from the cDNA plasmid into a testing vaccine for COVID-19 within 5 to 9 months and begin human testing. Medigen Vaccine Biologics Corporation complete the phase II clinical trial, the Central Epidemic Command Center might begin the vaccination with emergency authorization by TFDA. In order to meet the potential vaccine demands, EirGenix has already initiated the vaccine production since the end of February. Three batches of PPQ and 1 batch of GMP production have been completed, it is sufficient to provide sufficient amount of drug substance for MVC to make more than 4 million doses the final vaccine product.
- (B) EirGenix established an alliance with Panion and BF Biotech Inc. and AnTaimmu BioMed Co., Ltd. to co-develop a COVID-19 antigen rapid testing kits and obtained (a) EUA approval from Taiwan Food and Drug Administration (TFDA); (b) certification from India ICMR and obtained local sales and medical devices import permission; (c) certification from European Union CE-IVD (Reference Numbers:BS0266-2020); (d) Singapore Health

Sciences Authority (HAS) temporarily authorized permission; and e. Sale permission in Belgium.

III. Affirmation on business performance:

- A. Received the Grand Winner of Best Bioprocess Excellence in Taiwan in Singapore for 3 consecutive years.
- B. Awarded Best Bioprocess Excellence in Greater China Region from Biologics Manufacturing Asia.
- C. Awarded the 17th National Innovation Award.

(3) Financial revenue and expenditure and profitability analysis

The annual operating incomes are NTD 1,071,838 thousand dollars, which are mainly contributed by CDMO business and cooperative development revenue. The gross profit is NTD 750,667 thousand dollars with a 70% gross margin rate. The major expenditures of EirGenix's financial revenues and expenditures in 2020 were biosimilars development and contract development & manufacturing of biopharmaceuticals. The products are still in the development stage and require more investments for research and development funds, such as clinical study expenses, research and development material expenses, and research and development staff salaries. CDMO sales and other revenues are still unable to fully cover the research and development expenditures mentioned previously at this point, which is the main reason that caused EirGenix's loss. The investment of research and development expenditures now is to accumulate the energy for future profit growth after the product launches.

Unit: %

Item		Year	2019 (Individual)	2020 (Consolidated)
Financial Structure	Debt Ratio		45.73	50.31
	Long Term Funds to property, plant and equipment		156.35	172.42
Solvency	Current Ratio		218.24	232.70
	Quick Ratio		112.01	195.19
Profitability	Rate of return on assets		(26.47)	(28.10)
	Rate of return on equity		(43.67)	(55.40)
	Net Profit Margin		(180.83)	(97.19)
	Earnings per share (NTD)		\$-5.39	\$-5.41

(4) Budget implementation status

EirGenix had only set up an internal budget goal for 2020 and did not disclose the

financial forecast. The overall budget implementation has met the goal.

2. 2021 Business plan summary

(1) Business policy

EirGenix's business policy is to maintain the sustainable profit growth since the establishment. It came up with three major service items Considering three factors of the sales and developing time of drugs, risk value, and potential returns, three stages of the business focus have been set: 1. Contract Development and Manufacturing Organization (CDMO); 2. Biosimilar Development and 3. Me too and Novel biologics development to make the best of EirGenix's cGMP production factory, equipment, and high-end technology human resources.

(2) Estimated sales, and its basis, and important production and sales policy

EirGenix's biosimilars in development is still at the developing stage. The main revenue resource comes from Contract Development and Manufacturing Organization and authorized product collaborations. The senior management team proposes the overall goal and strategy, and the research and development team makes various development project plans. The project schedule for plan implementation and sales projection are made by feasibility analysis, market potential and financial evaluation.

3. EirGenix's future development strategy

(1) Short-term sales development plan

The short-term development strategy is "Build up foundation and move forward step by step". The strategy plans for products in-development and CDMO sales & marketing development are as follows:

I. Self-developed products:

- A. EG12014 will submit the drug certification applications (BLA- U.S. FDA and MAA - European Union EMA).
- B. EG1206A will submit IND and begin the phase I of clinical trial.
- C. EG62054 will complete cell line and 2-50 litre process development and analysis on biosimilarity
- D. EG13074 will complete preparation development and preclinical animal pharmacodynamic and toxicological tests, and will conduct preclinical meetings with the U.S. FDA.
- E. EG12021 will out-license the package of cell-line and manufacturing process after completing the process of 50L biosimilars. The out licensing will target on

the emerging countries.

II. CDMO sales:

In order to expand the current capacity and the needs for commercialized mass production of the future products, a biopharmaceutical plant is built in Hsinchu Biomedical Science Park. The current target is to cope with the phase III clinical trial of EG12014. It could also attract international and domestic clients with the late developmental stage products for large-scale production and commercial manufacturing after product launches. The overseas sales expansion has made a great progress in Japan. In addition, a subsidiary is set up in Germany to focus on the clinical development of on-going and future products in-development.

(2) Medium and long term sales development plan

The medium and long term development strategy is “Products are developing and launching one after another to promote stable growth in revenue. The strategy plans for products in-development and CDMO sales development are as follows:

I. Obtain drug certificates and product launch for products in-development.

II. CDMO sales:

Since the facility at the new factory in Zhubei is more suitable for products developed at late developmental stage (such as mass production for phase III clinical trials) or commercial production ; therefore, the short-term sales expansion will focus on the clients with early stage development and production projects which could be executed in Xizhi plant while establishing a global customer network for late stage development projects or mass production projects. Zhubei plant is expected to expand the production capacity to 24,000L after completion. It could meet the demand of various biopharmaceutical process development for mammal's cell. It can not only meet the demand for the products in-development, but also be useful for CDMO business in the future. Moreover, EirGenix is the only biopharmaceutical factory in Taiwan and China, and one of a few Asian biopharmaceutical factories that was GMP inspected and authorized by the Japanese official agency, PMDA. With this accreditation, it would increase the willingness and confidence of Japanese and international biotechnology companies to contract manufacturing and enhance sales promotion.



4. Effects by external competitive environment, legal environment, and overall business environment

The mission of EirGenix at the beginning is to provide high quality and cost-effective Contract Development and Manufacturing Organization and develop biosimilars with commercial values. The medium to long term goal is focusing on Niche Biologics development to benefit to the human and the society and improve the life quality. EirGenix insists on making the technology first with excellent quality as the foundation and be responsible for customer's success. The goal is becoming an international biotechnology and medicine company that begins in Taiwan and focuses on the global market

We would like to thank all of the shareholders, customers, and collaborating business partners for encouraging and supporting us, as well as the contribution and hard work from our employees. Together it brings prosperity and constant growth for EirGenix.

EirGenix, Inc.

Chairman: Chung-Hur Lee

President: Lee-Cheng Liu

Head of Accounting Department: Hsiu-Chuan Yang



Attachment II

EirGenix, Inc.

Audit Committee's Review Report

The Board of Directors has prepared EirGenix's 2020 Business Report, Financial Statement, and Deficit Offset Statement. The CPA Sheng-Wei Deng and Shu-Fen You of PricewaterhouseCoopers Taiwan was retained to audit EirGenix's Financial Statement and has issued an audit report relating to the Financial Statement.

The Business Report, Financial Statement, and Deficit Compensation Statement have been reviewed and determined to be correct and accurate by the Audit Committee member of EirGenix. According to relevant requirements of the Securities and Exchange Act and the Company Act, we hereby submit this report.

To

EirGenix, Inc. 2021 Annual Shareholders' Meeting

EirGenix, Inc.

Chairman of Audit Committee: Ming-Thaur Chang

Member of Audit Committee: Ming-Shen Chen

Member of Audit Committee: Fu-Shiow Yin

March 23, 2021

EirGenix, Inc.**Accumulated Loss and the Improvement Plan of Business Operations for the Fourth Quarter of 2020****1. Business policy**

The business policy of EirGenix, Inc. is sustainable growth since the establishment. It came up with three major service items considering three factors of the sales and developing time of drugs, risk value, and amount of rewards: 1. Contract Development and Manufacturing Organization (CDMO); 2. Development, production, manufacture, and sales of Biosimilars; and 3. Optimized biopharmaceuticals and development, manufacture, and sales of new biopharmaceuticals (Me too and Novel).

The current business model adopted at EirGenix, Inc. is a double-track system of Contract Development and Manufacturing Organization (CDMO) and Product Development to make the best of EirGenix's cGMP production factory, equipment, and high-end technology human resources. The core competitiveness of EirGenix, Inc. are two major production technologies: Mammalian cell development and Microbial strain fermentation development with professional capacities of development, manufacture, and analysis. It can keep track of the quality and cost control through a vertical integration operating model.

2. Reasons for loss in the past

EirGenix focuses on biosimilars, drug discovery, and biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The biosimilars development time is slightly shorter than new drug development. Generally speaking, it takes about 2 to 3 years for the stage of manufacturing process development in the labs, analysis on product features, and specification setting. With the drug review period and other schedules, it takes 6 to 8 years in total.

The business model adopted at EirGenix, Inc. is a double-track system of Contract Development and Manufacturing Organization (CDMO) and Product Development at the early establishing stage on December 21, 2012. With the considering factors of developing time, risk level, and amount of rewards, the business focuses on CDMO sales and the development and sales of biosimilars at this point. However, the substantial sales transferred from the pilot plant of the original Development Center for Biotechnology at the beginning were very limited. The CDMO sales were started from scratch. Thus, the fixed expenditures of biosimilars development, staff, and operations have caused the losses of EirGenix. The revenue from CDMO sales has been significantly increased in recent years compared with the early stage. The gross profit from

CDMO sales is able to cover EirGenix's sales and marketing expenses, and general and administrative expenses. Even though the signing bonus with Sandoz and the milestone payments of each stage for the self-developed product EG12014 are able to inject in the revenue, the revenue will have to be recognized step-by-step as the operating revenue. With the enormous developing expenses for sustained investment in biosimilars, EirGenix is still at losses.

As the continued growing sales of CDMO in recent years and advance of self-developed product EG12014 research and development schedule, EirGenix will receive milestone payments of each stage successively. Moreover, there is the royalty income of product sales in the authorized market shared at the contracted ratio after the product is launched. All of the above revenue would significantly improve EirGenix's financial structure.

3. Future operating strategy and improvement plan

(1) Short-term sales development plan

The short-term development strategy is "Build up foundation and move forward step by step". The strategy plans for products in-development and CDMO sales & marketing development are as follows:

I. Self-developed products:

- A. EG12014 will submit the drug certification applications (BLA- U.S. FDA and MAA - European Union EMA).
- B. EG1206A will submit IND and begin the phase I clinical trial.
- C. EG62054 will complete cell line and 2-50 litre process development and analysis on biosimilarity
- D. EG13074 will complete preparation development and preclinical animal pharmacodynamic and toxicological tests, and will conduct preclinical meetings with the U.S. FDA.
- E. EG12021 will out-license the package of cell-line and manufacturing process after completing the process of 50L biosimilars. The out licensing will target on the emerging countries.

II. CDMO sales:

In order to expand the current capacity and the needs for commercialized mass production of the future products, a biopharmaceutical plant is built in Hsinchu Biomedical Science Park. The current target is to cope with the phase III clinical trial of EG12014. It could also attract international and domestic clients with the late developmental stage products for large-scale production and commercial manufacturing after product launches. The oversea sales expansion has made a great progress in Japan. In addition, a subsidiary is set up in Germany to focus on the clinical development of on-going and future products in-development.

(2) Medium and long term sales development plan

The medium and long term development strategy is “Products are developing and launching one after another to promote stable growth in revenue. The strategy plans for products in-development and CDMO sales development are as follows:

I. Obtain drug certificates and product launch for products in-development.

II. CDMO sales:

Since the facility at the new factory in Zhubei is more suitable for products developed at late developmental stage (such as mass production for phase III clinical trials) or commercial production ; therefore, the short-term sales expansion will focus on the clients with early stage development and production projects which could be executed in Xizhi plant while establishing a global customer network for late stage development projects or mass production projects. Zhubei plant is expected to expand the production capacity to 24,000L after completion. It could meet the demand of various biopharmaceutical process development for mammal’s cell. It can not only meet the demand for the products in-development, but also be useful for CDMO business in the future. Moreover, EirGenix is the only biopharmaceutical factory in Taiwan and China, and one of a few Asian biopharmaceutical factories that was GMP inspected and authorized by the Japanese official agency, PMDA. With this accreditation, it would increase the willingness and confidence of Japanese and international biotechnology companies to contract manufacturing and enhance sales promotion.

4. Implementing status of the complete operating plan of 2020 Q4

Unit: NT thousand dollars

Item	Actual	Estimate	Increase (decrease) amount	Increase (decrease) percentage
Operating Revenue	1,071,838	1,065,601	6,237	0.59%
Operating Cost	321,171	321,680	(509)	(0.16%)
Gross Profit	750,667	743,921	6,746	0.91%
Operating Expenses	1,736,671	1,734,761	1,910	0.11%
Operating Income (Loss)	(986,004)	(990,840)	4,836	(0.49%)
Non- operating income (loss)	(55,319)	(46,693)	(8,626)	18.47%
Net loss before income tax	(1,041,323)	(1,037,533)	(3,790)	0.37%

EirGenix’s operating income in 2020 was increased by NT\$6,237,000 compared with the estimated amount. The increase in operating income and profit margin is mainly caused

by the improvement of CDMO production efficiency.

EirGenix's operating expense was increased by NT\$1,910,000 compared with the estimated amount due to the increase in compensation costs for recognized restricted employees in administrative expenses. The operating loss was decreased by NT\$4,836,000 because the operating margin is better than estimation. The actual non-operating expense is increased by NT\$8,626,000 compared with the estimated amount because of the adverse effects of exchange rate fluctuations on exchange gains and losses.

In conclusion, the net loss before tax was increased by NT\$3,790,000 compared to the estimated amount because of the adverse effects of non-operating income and expense compared with the estimated amount. Therefore, EirGenix's implementation shall be reasonable in accordance with the regular operational plan.

5. Conclusion

EirGenix's business policy is sustainable growth. At this stage, the CDMO business revenue is used to cover EirGenix's internal expenses stably. The biosimilars development is mature and can move on to the next stage of market sales. EirGenix may look for regional business partners as the product is successfully developed. The income of signing bonus from biosimilars in each year may balance out the expense for product research and development such as brand drug purchases, clinical trials on humans, and consulting fees for medical regulations in various countries, etc. With a two-pronged approach from the increase of CDMO sales and advance of product development, it is expected to reach the break-even point of profit and loss and begin to gain profits.

Attachment IV
EirGenix, Inc.
Status of the 1st Domestic Secured Convertible Corporate Bonds

Issuance	1st Secured Convertible Bond
Issuing date	May 29, 2020
Denomination	NT\$ 100,000
Offering Price	NT\$ 100 (par)
Total Denomination	NT\$ 300,000,000
Total price	NT\$ 300,000,000
Coupon rate	0%
Issue Duration	May 29, 2020 to May 29, 2023
Conversion Duration	Aug. 30, 2020 to May 29, 2023
Convertible Premium Rate	104.5%
Issue Conversion price	NT\$ 57.1
Latest Conversion price	NT\$ 53.3
Guarantor	Taichung Commercial Bank Co., Ltd.
Trustee	The Shanghai Commercial & Savings Bank, Ltd.
Underwriter	Yuanta Securities Co., Ltd.
Legal Counsel	Handsome Attorneys-at-Law
Auditor	PricewaterhouseCoopers Taiwan
Repayment	Please refer to the Procedures for Issuance and Conversion of 1st Domestic Secured Convertible Bond.
As of the printing date of this status, converted shares and unconverted amount.	Converted Shares 1,663,731 shares Unconverted amount NT\$205,000,000

EirGenix, Inc.

Comparison Table for the Rule of Corporate Social Responsibility Best Practice Principles

After the Revision	Before the Revision	Explanation
<p>Article 9:</p> <p>For the purpose of managing corporate social responsibility initiatives, the Company is advised to establishes an exclusively (or concurrently) dedicated unit <u>which is Finance Operations</u> to be in charge of proposing and enforcing the corporate social responsibility policies, systems, or relevant management guidelines, and concrete promotional plans and to report on the same to the Board of Directors on a periodic basis. (Omitted)</p>	<p>Article 9:</p> <p>For the purpose of managing corporate social responsibility initiatives, the Company is advised to establish an exclusively (or concurrently) dedicated unit to be in charge of proposing and enforcing the corporate social responsibility policies, systems, or relevant management guidelines, and concrete promotional plans and to report on the same to the Board of Directors on a periodic basis. (Omitted)</p>	<p>This article is revised in response to the plan of Corporate Governance.</p>
<p>Article 14:</p> <p>The Company is advised to establishes a dedicated unit or assign dedicated personnel <u>which is EMS</u> for drafting, promoting, and maintaining relevant environment management systems and concrete action plans, and should hold environment education courses for its managerial officers and other employees on a periodic basis.</p>	<p>Article 14:</p> <p>The Company is advised to establish a dedicated unit or assign dedicated personnel for drafting, promoting, and maintaining relevant environment management systems and concrete action plans, and should hold environment education courses for its managerial officers and other employees on a periodic basis.</p>	<p>This article is revised in response to the plan of Corporate Governance.</p>
<p>Article 31:</p> <p>These Principles shall be implemented after the board of directors grants the approval and shall be reported at a shareholders' meeting. The same procedure shall be followed for any amendments.</p> <p>This Principles were adopted on Apr. 17, 2018.</p> <p>The 1st amendment was made on Mar. 20, 2020.</p> <p><u>The 2nd amendment was made on Mar. 23, 2021.</u></p>	<p>Article 31:</p> <p>These Principles shall be implemented after the board of directors grants the approval and shall be reported at a shareholders' meeting. The same procedure shall be followed for any amendments.</p> <p>This Principles were adopted on Apr. 17, 2018.</p> <p>The 1st amendment was made on Mar. 20, 2020.</p>	<p>Add the date of amendments.</p>

Attachment VI
EirGenix, Inc.

Comparison Table for the Rule of Ethical Corporate Management Best Practice Principles

After the Revision	Before the Revision	Explanation
<p>Article 17 Organization and responsibility (Omitted)</p> <p>To achieve sound ethical corporate management, the Company has formed the <u>Legal Auditing Office</u> to be responsible for establishing and enforcing the ethical corporate management policies and prevention program. The Auditing Office shall be in charge of the following matters, and shall report to the board of directors on a regular basis (at least once a year): (Omitted)</p>	<p>Article 17 Organization and responsibility (Omitted)</p> <p>To achieve sound ethical corporate management, the Company has formed the Auditing Office to be responsible for establishing and enforcing the ethical corporate management policies and prevention program. The Auditing Office shall be in charge of the following matters, and shall report to the board of directors on a regular basis (at least once a year): (Omitted)</p>	<p>This article is revised in response to the plan of Corporate Governance.</p>
<p>Article 28</p> <p>This Principle were enacted on Apr. 17, 2018.</p> <p>Amended on Mar. 20, 2020 for the first time.</p> <p><u>Amended on Mar. 23, 2021 for the second time.</u></p>	<p>Article 28</p> <p>This Principle were enacted on Apr. 17, 2018.</p> <p>Amended on Mar. 20, 2020 for the first time.</p>	<p>Add the date of amendments.</p>

Attachment VII
EirGenix, Inc.

Comparison Table for Procedures for Ethical Management and Guidelines for Conduct

After the Revision	Before the Revision	Explanation
<p>Article 5 Responsible unit and duties</p> <p>This Corporation shall designate the <u>Legal Internal Audit</u> as the solely responsible unit (hereinafter, "responsible unit") under the board of directors and provide it with sufficient resources and competent personnel to be in charge of the amendment, implementation, interpretation, and advisory services with respect to these Procedures and Guidelines, the recording and filing of reports, and the monitoring of implementation. The responsible unit shall be in charge of the following matters and also submit regular reports (at least once a year) to the board of directors:</p> <p>(Omitted)</p>	<p>Article 5 Responsible unit and duties</p> <p>This Corporation shall designate the Internal Audit as the solely responsible unit (hereinafter, "responsible unit") under the board of directors and provide it with sufficient resources and competent personnel to be in charge of the amendment, implementation, interpretation, and advisory services with respect to these Procedures and Guidelines, the recording and filing of reports, and the monitoring of implementation. The responsible unit shall be in charge of the following matters and also submit regular reports (at least once a year) to the board of directors:</p> <p>(Omitted)</p>	<p>This article is revised in response to the plan of Corporate Governance.</p>
<p>Article 24 Enforcement</p> <p>(Omitted)</p> <p>This Procedures were enacted on April 17, 2018</p> <p>Amended on Mar. 20, 2020 for the first time.</p> <p><u>Amended on Mar. 23, 2021 for the second time.</u></p>	<p>Article 24 Enforcement</p> <p>(Omitted)</p> <p>This Procedures were enacted on April 17, 2018</p> <p>Amended on Mar. 20, 2020 for the first time.</p>	<p>Add the date of amendments.</p>

Attachment VIII

EirGenix, Inc.

Financial Statements and Independent Auditor's Report

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

EIRGENIX, INC.

Declaration of Consolidated Financial Statements of Affiliated Enterprises

For the year ended December 31, 2020, pursuant to “Criteria Governing Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises,” the entities that are required to be included in the consolidated financial statements of affiliates are the same as the entities required to be included in the consolidated financial statements of parent and subsidiary companies under International Financial Reporting Standard No. 10. Also, if relevant information that should be disclosed in the consolidated financial statements of affiliates has all been disclosed in the consolidated financial statements of parent and subsidiary companies, it shall not be required to prepare separate consolidated financial statements of affiliates.

Hereby declare,

EirGenix Inc.

Representative: Chung-Hur Lee

March 23, 2021

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of EirGenix Inc.

Opinion

We have audited the accompanying consolidated balance sheets of EirGenix Inc. and subsidiary (the "Group") as at December 31, 2020 and 2019, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2020 and 2019, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and generally accepted auditing standards in the Republic of China (ROC GAAS). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Group in accordance with the Code of Professional Ethics for Certified Public Accountants in the Republic of China (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Group's consolidated financial statements of the current period are stated as follows:

Accuracy of service revenue and authorisation and cooperative development revenue

Description

Refer to Note 4(26) for accounting policy on service revenue and authorisation and cooperative development revenue recognition, Note 5(2) for significant accounting estimates and assumptions, and Note 6(19) for details of operating revenue. The amount of service revenue and authorisation and cooperative development revenue for the year ended December 31, 2020 were NTD 572,344 thousand and NTD 460,799 thousand, respectively.

The Group's service revenue and authorisation and cooperative development revenue primarily arise from offering biopharmaceutical contract development and manufacturing services and authorising intellectual property rights of medicine development to pharmaceutical factory. Revenue is recognised based on the stage of completion at balance sheet date provided that such transaction amounts can be reliably estimated. Since the information process, recording and maintenance are done partly manually and the recognition of service revenue and authorisation and cooperative development revenue contained a high degree of uncertainty resulting in a complex calculation process, and revenue recognition is significant to the financial statements, we considered the accuracy of service revenue recognition a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

1. Obtained management's accounting policies on the service revenue and authorisation and cooperative development revenue recognition and confirmed that they are reasonable.
2. Sampled and examined the contract in order to confirm the judgement made by the management was in line with the contract and R.O.C. GAAP.
3. For the performance obligation which was satisfied over time, sampled and examined each data and assessed whether the method and parameter used to measure the completion of performance obligation are reasonable.
4. Recalculating the accuracy of amount recognised as revenue and respective timing.

Impairment assessment of property, plant and equipment and intangible assets - professional expertise

Description

Refer to Note 4(17) for accounting policy on impairment of non-financial assets, Note 5(2) for uncertainty of accounting estimates and assumptions in relation to property, plant and equipment and intangible assets and Note 6(8) and 6(10) for description of property, plant and equipment and intangible assets.

On December 31, 2020, property, plant and equipment amounted to NTD 1,851,850 thousand, which were constructed to extend the production capacity of GMP; intangible assets - professional expertise totally amounted to NTD 25,552 thousand, which are externally acquired expertise aiming to develop new drug. The Group assesses at each balance sheet date the fair value or recoverable value of those assets whether there is an indication that they are impaired based on internal and external information. Since the impairment indication assessment and information and assumptions used to assess recoverable amount of assets have significant impact to property, plant and equipment and intangible assets - professional expertise, we considered impairment assessment of property, plant and equipment and intangible assets - professional expertise a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

1. Reviewed and assessed the reasonability of each data in the impairment indications assessment.
2. Assessed the estimation procedure of future cash flows, and checked whether the cash flows listed in assessment is consistent with operation plans.
3. Interviewed management to discuss the Group's operations and reviewed the actual performance of prior years' operating plans in order to understand the Group's intention and ability and no significant postponement on research and development.
4. Assessed the reasonability of the significant assumption adopted on estimating cash flows.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the generally accepted accounting standards in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the generally accepted accounting standards in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant

ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Teng, Sheng-Wei

Yu, Shu-Fen

For and on behalf of PricewaterhouseCoopers, Taiwan

March 23, 2021

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

EIRGENIX INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

Assets		Notes	December 31, 2020		December 31, 2019	
			AMOUNT	%	AMOUNT	%
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 908,346	24	\$ 292,327	9
1110	Current financial assets at fair value through profit or loss	6(2)	600	-	-	-
1136	Current financial assets at amortised cost	6(3) and 8	113,920	3	-	-
1140	Current contract assets	6(19) and 7	133,038	3	60,932	2
1150	Notes receivable, net	6(4)	21,052	1	-	-
1170	Accounts receivable, net	6(4)	72,532	2	177,111	5
1200	Other receivables		3,114	-	5,743	-
1220	Current income tax assets		307	-	175	-
130X	Inventories	6(5)	160,932	4	163,968	5
1410	Prepayments	6(6)	79,937	2	346,268	10
1479	Other current assets		529	-	1,733	-
11XX	Total current assets		1,494,307	39	1,048,257	31
Non-current assets						
1517	Non-current financial assets at fair value through other comprehensive income	6(7)	5,956	-	-	-
1535	Non-current financial assets at amortised cost	6(3) and 8	8,526	-	11,158	-
1600	Property, plant and equipment, net	6(8) and 8	1,851,850	48	1,878,776	55
1755	Right-of-use assets	6(9) and 7	316,642	8	333,043	10
1780	Intangible assets	6(10)	33,129	1	42,434	1
1980	Other non-current financial assets	8	30,601	1	30,862	1
1990	Other non-current assets	6(8), 7 and 8	94,204	3	73,255	2
15XX	Total non-current assets		2,340,908	61	2,369,528	69
1XXX	Total assets		\$ 3,835,215	100	\$ 3,417,785	100

(Continued)

EIRGENIX INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity		Notes	December 31, 2020		December 31, 2019			
			AMOUNT	%	AMOUNT	%		
Current liabilities								
2130	Current contract liabilities	6(19) and 7	\$	209,570	6	\$	160,333	5
2170	Accounts payable			41,161	1		16,808	1
2200	Other payables	6(11)		269,389	7		178,800	5
2220	Other payables - related parties	7		4,069	-		1,626	-
2280	Current lease liabilities	7		18,770	1		16,861	-
2320	Long-term liabilities, current portion	6(13) and 8		90,620	2		104,300	3
2399	Other current liabilities			8,584	-		1,597	-
21XX	Total current liabilities			642,163	17		480,325	14
Non-current liabilities								
2527	Non-current contract liabilities	6(19)		64,232	2		115,995	4
2530	Bonds payable	6(12)		291,985	7		-	-
2540	Long-term borrowings	6(13) and 8		626,081	16		647,134	19
2570	Deferred tax liabilities	6(25)		366	-		-	-
2580	Non-current lease liabilities	7		304,771	8		319,078	9
2600	Net defined benefit liability - non-current			-	-		382	-
25XX	Total non-current liabilities			1,287,435	33		1,082,589	32
2XXX	Total liabilities			1,929,598	50		1,562,914	46
Equity								
	Capital	6(16)						
3110	Common stock			2,063,751	54		1,693,041	49
	Capital reserve	6(17)						
3200	Capital surplus			2,813,974	73		2,055,782	60
	Accumulated deficit	6(18)						
3350	Accumulated deficit		(2,930,919)	(76)	(1,889,249)	(55)
	Other equity interest							
3400	Other equity interest		(41,189)	(1)	(4,703)	-
3XXX	Total equity			1,905,617	50		1,854,871	54
	Significant contingent liabilities and unrecognised contract commitments	9						
	Significant events after the balance sheet date	6(16) and 11						
3X2X	Total liabilities and equity		\$	3,835,215	100	\$	3,417,785	100

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars, except for loss per share amounts)

			Year ended December 31			
		Notes	2020		2019	
Items			AMOUNT	%	AMOUNT	%
4000	Operating Revenue	6(19) and 7	\$ 1,071,838	100	\$ 476,085	100
5000	Operating Costs	6(5)(10)(24) and 7	(321,171)	(30)	(221,418)	(46)
5900	Gross Profit		<u>750,667</u>	<u>70</u>	<u>254,667</u>	<u>54</u>
	Operating Expenses	6(10)(24) and 7				
6100	Sales and marketing expenses		(26,649)	(2)	(25,004)	(5)
6200	General and administrative expenses		(148,300)	(14)	(117,724)	(25)
6300	Research and development expenses		(1,561,722)	(146)	(959,610)	(202)
6000	Total operating expenses		(1,736,671)	(162)	(1,102,338)	(232)
6900	Operating loss		(986,004)	(92)	(847,671)	(178)
	Non-operating Income and Expenses					
7100	Interest income	6(3)(20)	3,093	-	2,273	-
7010	Other income	6(21)	1,571	-	2,512	1
7020	Other gains and losses	6(2)(22)	(31,483)	(3)	486	-
7050	Finance costs	6(9)(23) and 7	(28,500)	(2)	(18,525)	(4)
7000	Total non-operating income and expenses		(55,319)	(5)	(13,254)	(3)
7900	Loss before income tax		(1,041,323)	(97)	(860,925)	(181)
7950	Income tax benefit	6(25)	(347)	-	-	-
8200	Net Loss		<u>(\$ 1,041,670)</u>	<u>(97)</u>	<u>(\$ 860,925)</u>	<u>(181)</u>
	Other Comprehensive Income					
	Components of other comprehensive income that will not be reclassified to profit or loss					
8316	Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(7)	\$ 180	-	\$ -	-
8310	Other comprehensive income that will not be reclassified to profit or loss		<u>180</u>	<u>-</u>	<u>-</u>	<u>-</u>
	Components of other comprehensive income that will be reclassified to profit or loss					
8361	Exchange differences on translation		98	-	-	-
8399	Income tax relating to components of other comprehensive income that will be reclassified to profit or loss	6(25)	(19)	-	-	-
8360	Other comprehensive income that will be reclassified to profit or loss		<u>79</u>	<u>-</u>	<u>-</u>	<u>-</u>
8300	Other Comprehensive Income		<u>\$ 259</u>	<u>-</u>	<u>\$ -</u>	<u>-</u>
8500	Total Comprehensive Loss		<u>(\$ 1,041,411)</u>	<u>(97)</u>	<u>(\$ 860,925)</u>	<u>(181)</u>
	Earnings per share	6(26)				
9750	Basic earnings per share		<u>(\$ 5.41)</u>	<u>(\$ 5.39)</u>		

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

		Equity attributable to owners of the parent										
		Capital Reserves						Other Equity Interest				
									Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Unearned compensation	Total equity	
	Notes	Common stock	Additional paid-in capital	Donated assets received	Employee stock options	Capital surplus, share options	Restricted stock to employees	Accumulated deficit	Exchange differences on translation of foreign financial statements			
<u>Year ended December 31, 2019</u>												
		\$ 1,490,664	\$ 1,616,674	\$ 1,096	\$ 9,527	\$ -	\$ 5,991	(\$ 1,028,324)	\$ -	\$ -	(\$ 7,923)	\$ 2,087,705
		-	-	-	-	-	-	(860,925)	-	-	-	(860,925)
		-	-	-	-	-	-	(860,925)	-	-	-	(860,925)
		200,090	414,130	-	-	-	-	-	-	-	-	614,220
	6(16)	-	-	-	1,816	-	-	-	-	-	-	1,816
	6(15)	4,560	5,518	-	(2,428)	-	-	-	-	-	-	7,650
	6(15)(16)	-	-	-	-	-	-	-	-	-	-	-
	6(15)(16)	(2,273)	-	-	-	-	2,273	-	-	-	-	-
	6(15)	-	-	-	-	-	-	-	-	-	3,465	3,465
		-	-	-	-	-	245	-	-	(245)	-	-
		-	259	-	-	-	(259)	-	-	-	-	-
		-	-	940	-	-	-	-	-	-	-	940
		\$ 1,693,041	\$ 2,036,581	\$ 2,036	\$ 8,915	\$ -	\$ 8,250	(\$ 1,889,249)	\$ -	\$ -	(\$ 4,703)	\$ 1,854,871
<u>Year ended December 31, 2020</u>												
		\$ 1,693,041	\$ 2,036,581	\$ 2,036	\$ 8,915	\$ -	\$ 8,250	(\$ 1,889,249)	\$ -	\$ -	(\$ 4,703)	\$ 1,854,871
		-	-	-	-	-	-	(1,041,670)	-	-	-	(1,041,670)
		-	-	-	-	-	-	-	79	180	259	-
		-	-	-	-	-	-	(1,041,670)	79	180	-	(1,041,411)
	6(16)	350,000	662,427	-	-	-	-	-	-	-	-	1,012,427
	6(15)	-	15,330	-	-	-	-	-	-	-	-	15,330
	6(15)	-	-	-	6,720	-	-	-	-	-	-	6,720
	6(15)(16)	3,997	8,122	-	(1,837)	-	-	-	-	-	-	10,282
	6(15)(16)	18,384	-	-	-	-	57,703	-	-	-	(76,087)	-
	6(15)(16)	(1,671)	-	-	-	-	1,671	-	-	-	-	-
	6(15)	-	-	-	-	-	-	-	-	-	39,342	39,342
		-	14,964	-	-	-	(14,964)	-	-	-	-	-
	6(12)	-	-	-	-	8,056	-	-	-	-	-	8,056
		\$ 2,063,751	\$ 2,737,424	\$ 2,036	\$ 13,798	\$ 8,056	\$ 52,660	(\$ 2,930,919)	\$ 79	\$ 180	(\$ 41,448)	\$ 1,905,617

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

		Year ended December 31	
	Notes	2020	2019
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Loss before tax		(\$ 1,041,323)	(\$ 860,925)
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation	6(8)(9)(24)	158,217	99,658
Amortization	6(10)(24)	13,936	13,994
Net loss on financial assets or liabilities at fair value	6(2)(22)	240	-
Interest expense	6(23)	28,500	18,525
Interest income	6(20)	(3,093)	(2,273)
Compensation costs of employee stock options	6(15)(24)	61,392	5,281
Gain on lease modification	6(22)	(14)	-
Changes in operating assets and liabilities			
Changes in operating assets			
Current contract assets	(72,106)	44,662
Notes receivable, net	(21,052)	-
Accounts receivable, net		98,803	(171,232)
Other receivables		2,593	4,810
Inventory		3,036	(123,344)
Prepayments		261,018	(145,473)
Other current assets		1,204	(824)
Changes in operating liabilities			
Current contract liabilities	(2,526)	255,755
Accounts payable		24,353	9,599
Other payables		78,463	83,914
Other payables - related parties		2,443	(382)
Other current liabilities		6,987	(312)
Cash outflow generated from operations	(398,929)	(768,567)
Interest received		3,129	2,356
Interest paid	(23,330)	(17,892)
Income tax received		98	115
Income tax paid	(230)	(77)
Net cash flows used in operating activities	(419,262)	(784,065)
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at amortized cost	(111,288)	-
Acquisition of property, plant and equipment	6(8)(27)	(38,146)	(408,043)
Acquisition of intangible assets	6(10)(27)	(4,865)	(2,269)
Decrease (increase) in refundable deposits	(315)	(53,933)
Increase in other non-current financial assets		261	(406)
Increase in other non-current assets	(74,004)	(19,605)
Net cash flows used in investing activities	(228,357)	(484,256)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Issuance of corporate bonds	6(28)	297,277	-
Payments of long-term borrowings	6(28)	715,935	166,800
Repayments of long-term borrowings	6(28)	(754,200)	(83,800)
Increase in guarantee deposits received	(382)	(576)
Repayments of lease principal	6(28)	(17,785)	(17,333)
Issuance of common stocks		1,012,427	614,220
Employee stock options exercised		10,282	7,650
Cash donation of by shareholder		-	940
Net cash flows from financing activities		1,263,554	687,901
Effect of exchange rate		84	-
Net increase (decrease) in cash and cash equivalents		616,019	(580,420)
Cash and cash equivalents at beginning of year		292,327	872,747
Cash and cash equivalents at end of year		<u>\$ 908,346</u>	<u>\$ 292,327</u>

The accompanying notes are an integral part of these consolidated financial statements.

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of EirGenix Inc.

Opinion

We have audited the accompanying parent company only balance sheets of EirGenix Inc. (the "Company") as at December 31, 2020 and 2019, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2020 and 2019, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and generally accepted auditing standards in the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Parent company only Financial Statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountants in the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's 2020 parent company only financial statements of the current period. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Company's 2020 parent company only financial statements are stated as follows:

Accuracy of service revenue and authorisation and cooperative development revenue

Description

Refer to Note 4(26) for accounting policy on service revenue and authorisation and cooperative development revenue recognition, Note 5(2) for significant accounting estimates and assumptions, and Note 6(20) for details of operating revenue. The amount of service revenue and authorisation and cooperative development revenue for the year ended December 31, 2020 were NTD 572,344 thousand and NTD 460,799 thousand, respectively.

The Company's service revenue and authorisation and cooperative development revenue primarily arise from offering biopharmaceutical contract development and manufacturing services and authorising intellectual property rights of medicine development to pharmaceutical factory. Revenue is recognised based on the stage of completion at the balance sheet date provided that such transaction amounts can be reliably estimated. Since the information process, recording and maintenance are done partly manually and the recognition of service revenue and authorisation and cooperative development revenue contained a high degree of uncertainty resulting in a complex calculation process, and revenue recognition is significant to the financial statements, we considered the accuracy of service revenue recognition a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

1. Obtained management's accounting policies on the service revenue and authorisation and cooperative development revenue recognition and confirmed that they are reasonable.
2. Sampled and examined the contract in order to confirm the judgement made by the management was in line with the contract and R.O.C. GAAP.
3. For the performance obligation which was satisfied over time, sampled and examined each data and assessed whether the method and parameter used to measure the completion of performance obligation are reasonable.
4. Recalculating the accuracy of amount recognised as revenue and respective timing.

Impairment assessment of property, plant and equipment and intangible assets - professional expertise

Description

Refer to Note 4(17) for accounting policy on impairment of non-financial assets, Note 5(2) for uncertainty of accounting estimates and assumptions in relation to property, plant and equipment and intangible assets and Notes 6(9) and 6(11) for description of property, plant and equipment and intangible assets.

On December 31, 2020, property, plant and equipment amounted to NTD 1,851,325 thousand, which were constructed to extend the production capacity of GMP; and intangible assets - professional expertise amounted to NTD 25,552 thousand, which are externally acquired expertise aiming to develop new drugs. The Company assesses at each balance sheet date the fair value or recoverable value of those assets whether there is an indication that they are impaired based on internal and external information. Since the impairment indication assessment and information and assumptions used to assess recoverable amount of assets have significant impact to property, plant and equipment and intangible assets - professional expertise, we considered impairment assessment of property, plant and equipment and intangible assets - professional expertise a key audit matter.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

1. Reviewed and assessed the reasonableness of each data in the impairment indications assessment.
2. Assessed the estimation procedure of future cash flows, and checked whether the cash flows listed in assessment is consistent with operating plans.
3. Interviewed management to discuss the Company's operations and reviewed the actual performance of prior years' operating plans in order to understand the Company's intention and ability and no ascertained whether there was significant postponement on research and development.
4. Assessed the reasonableness of the significant assumptions adopted on estimating cash flows.

Responsibilities of management and those charged with governance for the parent company only financial statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the generally accepted accounting standards in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the generally accepted accounting standards in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company and its subsidiaries to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Teng, Sheng-Wei

Yu, Shu-Fen

For and on behalf of PricewaterhouseCoopers, Taiwan

March 23, 2021

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

EIRGENIX INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

Assets		Notes	December 31, 2020		December 31, 2019	
			AMOUNT	%	AMOUNT	%
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 905,956	24	\$ 292,327	9
1110	Current financial assets at fair value through profit or loss	6(2)	600	-	-	-
1136	Current financial assets at amortised cost	6(3) and 8	113,920	3	-	-
1140	Current contract assets	6(20) and 7	133,038	3	60,932	2
1150	Notes receivable, net	6(4)	21,052	1	-	-
1170	Accounts receivable, net	6(4)	72,532	2	177,111	5
1200	Other receivables		3,114	-	5,743	-
1220	Current income tax assets		307	-	175	-
130X	Inventories	6(5)	160,932	4	163,968	5
1410	Prepayments	6(6)	79,486	2	346,268	10
1479	Other current assets		529	-	1,733	-
11XX	Total current assets		1,491,466	39	1,048,257	31
Non-current assets						
1517	Non-current financial assets at fair value through other comprehensive income	6(7)	5,956	-	-	-
1535	Non-current financial assets at amortised cost	6(3) and 8	8,526	-	11,158	-
1550	Investments accounted for using equity method	6(8) and 7	2,678	-	-	-
1600	Property, plant and equipment, net	6(9) and 8	1,851,325	48	1,878,776	55
1755	Right-of-use assets	6(10) and 7	314,662	8	333,043	10
1780	Intangible assets	6(11)	32,840	1	42,434	1
1980	Other non-current financial assets	8	30,601	1	30,862	1
1990	Other non-current assets	6(9), 7 and 8	94,204	3	73,255	2
15XX	Total non-current assets		2,340,792	61	2,369,528	69
1XXX	Total assets		\$ 3,832,258	100	\$ 3,417,785	100

(Continued)

EIRGENIX INC.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity		Notes	December 31, 2020		December 31, 2019	
			AMOUNT	%	AMOUNT	%
Current liabilities						
2130	Current contract liabilities	6(20) and 7	\$ 209,570	6	\$ 160,333	5
2170	Accounts payable		41,161	1	16,808	1
2200	Other payables	6(12)	265,838	7	178,800	5
2220	Other payables - related parties	7	6,654	-	1,626	-
2280	Current lease liabilities	7	17,371	1	16,861	-
2320	Long-term liabilities, current portion	6(14) and 8	90,620	2	104,300	3
2399	Other current liabilities		8,584	-	1,597	-
21XX	Total current liabilities		639,798	17	480,325	14
Non-current liabilities						
2527	Non-current contract liabilities	6(20)	64,232	2	115,995	4
2530	Bonds payable	6(13)	291,985	7	-	-
2540	Long-term borrowings	6(14) and 8	626,081	16	647,134	19
2570	Deferred tax liabilities	6(26)	366	-	-	-
2580	Non-current lease liabilities	7	304,179	8	319,078	9
2600	Net defined benefit liability - non-current		-	-	382	-
25XX	Total non-current liabilities		1,286,843	33	1,082,589	32
2XXX	Total liabilities		1,926,641	50	1,562,914	46
Equity						
	Capital	6(17)				
3110	Common stock		2,063,751	54	1,693,041	49
	Capital reserve	6(18)				
3200	Capital surplus		2,813,974	73	2,055,782	60
	Accumulated deficit	6(19)				
3350	Accumulated deficit		(2,930,919)	(76)	(1,889,249)	(55)
	Other equity interest					
3400	Other equity interest		(41,189)	(1)	(4,703)	-
3XXX	Total equity		1,905,617	50	1,854,871	54
	Significant contingent liabilities and unrecognised contract commitments	9				
	Significant events after the balance sheet date	6(17) and 11				
3X2X	Total liabilities and equity		\$ 3,832,258	100	\$ 3,417,785	100

The accompanying notes are an integral part of these parent company only financial statements.

EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars, for loss per share amounts)

			Year ended December 31			
			2020		2019	
Items	Notes		AMOUNT	%	AMOUNT	%
4000 Operating Revenue	6(20) and 7		\$ 1,071,838	100	\$ 476,085	100
5000 Operating Costs	6(5)(11)(25) and 7	(321,171)	(30)	(221,418)	(46)
5900 Gross Profit			750,667	70	254,667	54
Operating Expenses	6(11)(25) and 7					
6100 Sales and marketing expenses		(26,928)	(2)	(25,004)	(5)
6200 General and administrative expenses		(148,300)	(14)	(117,724)	(25)
6300 Research and development expenses		(1,563,205)	(146)	(959,610)	(202)
6000 Total operating expenses		(1,738,433)	(162)	(1,102,338)	(232)
6900 Operating loss		(987,766)	(92)	(847,671)	(178)
Non-operating Income and Expenses						
7100 Interest income	6(3)(21)		3,093	-	2,273	-
7010 Other income	6(22)		1,571	-	2,512	1
7020 Other gains and losses	6(2)(23)	(31,483)	(3)	486	-
7050 Finance costs	6(10)(24) and 7	(28,473)	(2)	(18,525)	(4)
7070 Share of profit of associates and joint ventures accounted for using equity method	6(8)		1,735	-	-	-
7000 Total non-operating income and expenses		(53,557)	(5)	(13,254)	(3)
7900 Loss before income tax		(1,041,323)	(97)	(860,925)	(181)
7950 Income tax benefit	6(26)	(347)	-	-	-
8200 Net Loss		(<u>1,041,670</u>)	<u>(97)</u>	(<u>860,925</u>)	<u>(181)</u>
Other Comprehensive Income						
Components of other comprehensive income that will not be reclassified to profit or loss						
8316 Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(7)		\$ 180	-	\$ -	-
8310 Other comprehensive income that will not be reclassified to profit or loss			180	-	-	-
Components of other comprehensive income that will be reclassified to profit or loss						
8361 Exchange differences on translation			98	-	-	-
8399 Income tax relating to components of other comprehensive income that will be reclassified to profit or loss	6(26)	(19)	-	-	-
8360 Other comprehensive income that will be reclassified to profit or loss			79	-	-	-
8300 Other Comprehensive Income			<u>\$ 259</u>	<u>-</u>	<u>\$ -</u>	<u>-</u>
8500 Total Comprehensive Loss		(<u>1,041,411</u>)	<u>(97)</u>	(<u>860,925</u>)	<u>(181)</u>
Loss per share	6(27)					
9750 Basic loss per share from continuing operations		(<u>5.41</u>)	(<u>5.39</u>)	

The accompanying notes are an integral part of these parent company only financial statements.

EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

		Capital Reserves							Other equity interest			
									Exchange differences on translation of foreign financial statements	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	Unearned compensation	Total equity
	Notes	Common stock	Additional paid-in capital	Donated assets received	Employee stock options	Capital surplus, share options	Restricted stock to employees	Accumulated deficit				
<u>Year ended December 31, 2019</u>												
		\$ 1,490,664	\$ 1,616,674	\$ 1,096	\$ 9,527	\$ -	\$ 5,991	(\$ 1,028,324)	\$ -	\$ -	(\$ 7,923)	\$ 2,087,705
		-	-	-	-	-	-	(860,925)	-	-	-	(860,925)
		-	-	-	-	-	-	(860,925)	-	-	-	(860,925)
Issuance of shares	6(17)	200,090	414,130	-	-	-	-	-	-	-	-	614,220
Compensation costs of employee stock options	6(16)	-	-	-	1,816	-	-	-	-	-	-	1,816
Employee stock options exercised	6(16)(17)	4,560	5,518	-	(2,428)	-	-	-	-	-	-	7,650
Redemption of employee restricted stock	6(16)(17)	(2,273)	-	-	-	-	2,273	-	-	-	-	-
Compensation costs of restricted stocks	6(16)	-	-	-	-	-	-	-	-	-	3,465	3,465
Change in estimated compensation costs of restricted stocks		-	-	-	-	-	245	-	-	-	(245)	-
Restricted stocks vested		-	259	-	-	-	(259)	-	-	-	-	-
Cash donation of Shareholder		-	-	940	-	-	-	-	-	-	-	940
Balance at December 31, 2019		\$ 1,693,041	\$ 2,036,581	\$ 2,036	\$ 8,915	\$ -	\$ 8,250	(\$ 1,889,249)	\$ -	\$ -	(\$ 4,703)	\$ 1,854,871
<u>Year ended December 31, 2020</u>												
		\$ 1,693,041	\$ 2,036,581	\$ 2,036	\$ 8,915	\$ -	\$ 8,250	(\$ 1,889,249)	\$ -	\$ -	(\$ 4,703)	\$ 1,854,871
		-	-	-	-	-	-	(1,041,670)	-	-	-	(1,041,670)
Other comprehensive income		-	-	-	-	-	-	-	79	180	-	259
Total comprehensive income		-	-	-	-	-	-	(1,041,670)	79	180	-	(1,041,411)
Issuance of shares	6(17)	350,000	662,427	-	-	-	-	-	-	-	-	1,012,427
Cash capital increase reserved for employee preemption	6(16)	-	15,330	-	-	-	-	-	-	-	-	15,330
Compensation costs of employee stock options	6(16)	-	-	-	6,720	-	-	-	-	-	-	6,720
Employee stock options exercised	6(16)(17)	3,997	8,122	-	(1,837)	-	-	-	-	-	-	10,282
Issuance of restricted stocks	6(16)(17)	18,384	-	-	-	-	57,703	-	-	-	(76,087)	-
Redemption of employee restricted stock	6(16)(17)	(1,671)	-	-	-	-	1,671	-	-	-	-	-
Compensation costs of restricted stocks	6(16)	-	-	-	-	-	-	-	-	-	39,342	39,342
Restricted stocks vested		-	14,964	-	-	-	(14,964)	-	-	-	-	-
Issuance of convertibal bonds	6(13)	-	-	-	-	8,056	-	-	-	-	-	8,056
Balance at December 31, 2020		\$ 2,063,751	\$ 2,737,424	\$ 2,036	\$ 13,798	\$ 8,056	\$ 52,660	(\$ 2,930,919)	\$ 79	\$ 180	(\$ 41,448)	\$ 1,905,617

The accompanying notes are an integral part of these parent company only financial statements.

EIRGENIX INC.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2020 AND 2019
(Expressed in thousands of New Taiwan dollars)

		Year ended December 31	
	Notes	2020	2019
CASH FLOWS FROM OPERATING ACTIVITIES			
Loss before tax		(\$ 1,041,323)	(\$ 860,925)
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation	6(9)(10)(25)	157,349	99,658
Amortization	6(11)(25)	13,928	13,994
Net loss on financial assets or liabilities at fair value	6(2)(23)	240	-
Interest expense	6(24)	28,473	18,525
Interest income	6(21)	(3,093)	(2,273)
Compensation costs of employee stock options	6(16)(25)	61,392	5,281
Share of loss of associates and joint ventures accounted for using equity method	6(8)	(1,735)	-
Gain on lease modification	6(23)	(14)	-
Changes in operating assets and liabilities			
Changes in operating assets			
Current contract assets		(72,106)	44,662
Notes receivable, net		(21,052)	-
Accounts receivable, net		98,803	(171,232)
Other receivables		2,593	4,810
Inventory		3,036	(123,344)
Prepayments		261,469	(145,473)
Other current assets		1,204	(824)
Changes in operating liabilities			
Current contract liabilities		(2,526)	255,755
Accounts payable		24,353	9,599
Other payables		74,904	83,914
Other payables - related parties		5,028	(382)
Other current liabilities		6,987	(312)
Cash outflow generated from operations		(402,090)	(768,567)
Interest received		3,129	2,356
Interest paid		(23,303)	(17,892)
Income tax received		98	115
Income tax paid		(230)	(77)
Net cash flows used in operating activities		(422,396)	(784,065)
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of financial assets at amortized cost		(111,288)	-
Acquisition of investments accounted for using	6(8) and 7	(845)	-
Acquisition of property, plant and equipment	6(9)(28)	(37,534)	(408,043)
Acquisition of intangible assets	6(11)(28)	(4,579)	(2,269)
Increase in refundable deposits		(315)	(53,933)
Decrease(increase) in other non-current financial assets		261	(406)
Increase in other non-current assets		(74,004)	(19,605)
Net cash flows used in investing activities		(228,304)	(484,256)
CASH FLOWS FROM FINANCING ACTIVITIES			
Issuance of corporate bonds	6(29)	297,277	-
Payments of long-term borrowings	6(29)	715,935	166,800
Repayments of long-term borrowings	6(29)	(754,200)	(83,800)
Increase in guarantee deposits received		(382)	(576)
Repayments of lease principal	6(29)	(17,010)	(17,333)
Issuance of common stocks		1,012,427	614,220
Employee stock options exercised		10,282	7,650
Cash donation of Shareholder		-	940
Net cash flows from financing activities		1,264,329	687,901
Net increase (decrease) in cash and cash equivalents		613,629	(580,420)
Cash and cash equivalents at beginning of year		292,327	872,747
Cash and cash equivalents at end of year		\$ 905,956	\$ 292,327

The accompanying notes are an integral part of these parent company only financial statements.

Attachment IX
EirGenix, Inc.
Comparison Table for the Company's Articles of Incorporation

After the Revision	Before the Revision	Explanation
<p>Article 6:</p> <p>The Company has a total capital amounting to three <u>four</u> billion New Taiwan Dollars, divided into three <u>four</u> hundred million shares at ten New Taiwan Dollars par value per share, issued in installments. The Board of Directors is authorized to issue the unissued shares in installments, from which twelve million shares shall be reserved for issuance upon the exercise of any stock options, preferred shares with warrants, or equity warrant bonds.</p>	<p>Article 6:</p> <p>The Company has a total capital amounting to three billion New Taiwan Dollars, divided into three hundred million shares at ten New Taiwan Dollars par value per share, issued in installments. The Board of Directors is authorized to issue the unissued shares in installments, from which twelve million shares shall be reserved for issuance upon the exercise of any stock options, preferred shares with warrants, or equity warrant bonds.</p>	Increasing Company's capital amount and issuing shares.
<p>Article 27:</p> <p>The Procedure was enacted on December 20th, 2012.</p> <p>The 1st amendment was made on March 14th, 2013.</p> <p>The 2nd amendment was made on June 14th, 2013.</p> <p>The 3rd amendment was made on July 24th, 2013.</p> <p>The 4th amendment was made on June 20th, 2014.</p> <p>The 5th amendment was made on June 23rd, 2015.</p> <p>The 6th amendment was made on June 3rd, 2016.</p> <p>The 7th amendment was made on September 13th, 2016.</p> <p>The 8th amendment was made on June 12th, 2018.</p> <p>The 9th amendment was made on</p>	<p>Article 27:</p> <p>The Procedure was enacted on December 20th, 2012.</p> <p>The 1st amendment was made on March 14th, 2013.</p> <p>The 2nd amendment was made on June 14th, 2013.</p> <p>The 3rd amendment was made on July 24th, 2013.</p> <p>The 4th amendment was made on June 20th, 2014.</p> <p>The 5th amendment was made on June 23rd, 2015.</p> <p>The 6th amendment was made on June 3rd, 2016.</p> <p>The 7th amendment was made on September 13th, 2016.</p> <p>The 8th amendment was made on June 12th, 2018.</p> <p>The 9th amendment was made on</p>	Add the date of amendments.

After the Revision	Before the Revision	Explanation
<p>March 21st, 2019.</p> <p>The 10th amendment was made on June 12th, 2019.</p> <p>The 11th amendment was made on November 27th, 2019.</p> <p><u>The 12th amendment was made on August 3rd, 2021.</u></p>	<p>March 21st, 2019.</p> <p>The 10th amendment was made on June 12th, 2019.</p> <p>The 11th amendment was made on November 27th, 2019.</p>	

EirGenix, Inc.

Comparison Table for the Rules of Procedure for Shareholders Meetings

After the Revision	Before the Revision	Explanation
<p>Article 6:</p> <p>Attendance at shareholders meetings shall be calculated based on numbers of shares. The number of shares in attendance shall be calculated according to the shares indicated by the attendance book and sign-in cards handed in plus the number of shares whose voting rights are exercised by correspondence or electronically.</p> <p>The chair shall call the meeting to order at the appointed meeting time <u>and disclose information concerning the number of nonvoting shares and number of shares represented by shareholders attending the meeting.</u> However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement, provided that no more than two such postponements, for a combined total of no more than one hour, may be made. If the quorum is not met after two postponements and the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned.</p> <p>(Omitted)</p>	<p>Article 6:</p> <p>Attendance at shareholders meetings shall be calculated based on numbers of shares. The number of shares in attendance shall be calculated according to the shares indicated by the attendance book and sign-in cards handed in plus the number of shares whose voting rights are exercised by correspondence or electronically.</p> <p>The chair shall call the meeting to order at the appointed meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement, provided that no more than two such postponements, for a combined total of no more than one hour, may be made. If the quorum is not met after two postponements and the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned.</p> <p>(Omitted)</p>	<p>The revisions to this Article are proposed in accordance with applicable laws and regulations.</p>
<p>Article 8:</p> <p>(Omitted)</p> <p>The reasons for convening a</p>	<p>Article 8:</p> <p>(Omitted)</p> <p>The reasons for convening a</p>	<p>The revisions to this Article are</p>

After the Revision	Before the Revision	Explanation
<p>shareholders meeting shall be specified in the meeting notice and public announcement. With the consent of the addressee, the meeting notice may be given in electronic form.</p> <p>Election or dismissal of directors, amendments to the articles of incorporation, reduction of capital, application for the approval of ceasing its status as a public company, approval of competing with the company by directors, surplus profit distributed in the form of new shares, reserve distributed in the form of new shares, the dissolution, merger, or demerger of the corporation, or any matter under Article 185, paragraph 1 of the Company Act, Articles 26-1 and 43-6 of the Securities Exchange Act, Articles 56-1 and 60-2 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers shall be set out and the essential contents explained in the notice of the reasons for convening the shareholders meeting.</p> <p>None of the above matters may be raised by an extraordinary motion; the essential contents may be posted on the website designated by the competent authority in charge of securities affairs or the corporation, and such website shall be indicated in the above notice.</p> <p>Where re-election of all directors as well as their inauguration date is stated in the notice of the reasons for convening the shareholders meeting, after the completion of the re-election in</p>	<p>shareholders meeting shall be specified in the meeting notice and public announcement. With the consent of the addressee, the meeting notice may be given in electronic form.</p> <p>Election or dismissal of directors, amendments to the articles of incorporation, reduction of capital, application for the approval of ceasing its status as a public company, approval of competing with the company by directors, surplus profit distributed in the form of new shares, reserve distributed in the form of new shares, the dissolution, merger, or demerger of the corporation, or any matter under Article 185, paragraph 1 of the Company Act, Articles 26-1 and 43-6 of the Securities Exchange Act, Articles 56-1 and 60-2 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers shall be set out and the essential contents explained in the notice of the reasons for convening the shareholders meeting.</p> <p>None of the above matters may be raised by an extraordinary motion; the essential contents may be posted on the website designated by the competent authority in charge of securities affairs or the corporation, and such website shall be indicated in the above notice.</p> <p>Where re-election of all directors as well as their inauguration date is stated in the notice of the reasons for convening the shareholders meeting, after the completion of the re-election in</p>	<p>proposed in accordance with applicable laws and regulations.</p>

After the Revision	Before the Revision	Explanation
<p>said meeting such inauguration date may not be altered by any extraordinary motion or otherwise in the same meeting.</p> <p>A shareholder holding one percent or more of the total number of issued shares may submit to this Corporation a proposal for discussion at a regular shareholders meeting. The number of items so proposed is limited to one only, and no proposal containing more than one item will be included in the meeting agenda. If, however, A shareholder propose a recommendation for urging the corporation to promote public interests or fulfill its social responsibilities, the board of director may still include in agenda. When the circumstances of any subparagraph of Article 172-1, paragraph 4 of the Company Act apply to a proposal put forward by a shareholder, the board of directors may exclude it from the agenda. When the circumstances of any subparagraph of Article 172-1, paragraph 4 of the Company Act apply to a proposal put forward by a shareholder, the board of directors may exclude it from the agenda. A shareholder may propose a recommendation for urging the corporation to promote public interests or fulfill its social responsibilities, provided procedurally the number of items so proposed is limited only to one in accordance with Article 172-1 of the Company Act, and no proposal</p>	<p>said meeting such inauguration date may not be altered by any extraordinary motion or otherwise in the same meeting.</p> <p>A shareholder holding one percent or more of the total number of issued shares may submit to this Corporation a proposal for discussion at a regular shareholders meeting. The number of items so proposed is limited to one only, and no proposal containing more than one item will be included in the meeting agenda. If, however, A shareholder propose a recommendation for urging the corporation to promote public interests or fulfill its social responsibilities, the board of director may still include in agenda. When the circumstances of any subparagraph of Article 172-1, paragraph 4 of the Company Act apply to a proposal put forward by a shareholder, the board of directors may exclude it from the agenda.</p> <p>(Omitted)</p>	

After the Revision	Before the Revision	Explanation
containing more than one item will be included in the meeting agenda. (Omitted)		
<p>Article 12:</p> <p>The election of directors at a shareholders meeting shall be held in accordance with the rules for election of directors adopted by this Corporation, <u>and the voting results shall be announced on-site immediately, including the names of those elected as directors and supervisors and the numbers of votes with which they were elected, and the names of directors and supervisors not elected and number of votes they received.</u></p> <p>The ballots for the election referred to in the preceding paragraph shall be sealed with the signatures of the monitoring personnel and kept in proper custody for at least one year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the ballots shall be retained until the conclusion of the litigation.</p>	<p>Article 12:</p> <p>The election of directors at a shareholders meeting shall be held in accordance with the rules for election of directors adopted by this Corporation. The ballots for the election referred to in the preceding paragraph shall be sealed with the signatures of the monitoring personnel and kept in proper custody for at least one year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the ballots shall be retained until the conclusion of the litigation.</p>	<p>The revisions to this Article are proposed in accordance with applicable laws and regulations.</p>
<p>Article 18:</p> <p>These Rules were enacted on Jul. 24, 2013</p> <p>Amended on Sep. 13, 2016 for the first time.</p> <p>Amended on Jun. 12, 2018 for the second time.</p> <p>Amended on Jun. 29, 2020 for the third time.</p> <p><u>Amended on August 3rd, 2021 for the fourth time.</u></p>	<p>Article 18:</p> <p>These Rules were enacted on Jul. 24, 2013</p> <p>Amended on Sep. 13, 2016 for the first time.</p> <p>Amended on Jun. 12, 2018 for the second time.</p> <p>Amended on Jun. 29, 2020 for the third time.</p>	<p>Add the date of amendments.</p>

EirGenix, Inc.
**Comparison Table for the Regulations Governing Procedure for
Election of Directors**

After the Revision	Before the Revision	Explanation
<p>Article 4:</p> <p>If a candidate is a shareholder, a voter must enter the candidate's account name and shareholder account number in the "candidate" column of the ballot, and the candidate's shareholder account number may also be noted; for a non-shareholder, the voter shall enter the candidate's full name, and the identity number. However, when the candidate is a governmental organization or juristic person shareholder, the name of the governmental organization or juristic person shareholder shall be entered in the "candidate" column for account name of the ballot, or the name of the representative may be entered instead. When there are multiple representatives, the names of each respective representative shall be entered.</p> <p><u>When the number of directors falls short by one third of the total number prescribed in this Corporation's articles of incorporation, this Corporation shall call a special shareholders meeting within 60 days from the date of occurrence to hold a by-election to fill the vacancies.</u></p> <p><u>When the number of independent directors falls below that required under</u></p>	<p>Article 4:</p> <p>If a candidate is a shareholder, a voter must enter the candidate's account name and shareholder account number in the "candidate" column of the ballot, and the candidate's shareholder account number may also be noted; for a non-shareholder, the voter shall enter the candidate's full name, and the identity number. However, when the candidate is a governmental organization or juristic person shareholder, the name of the governmental organization or juristic person shareholder shall be entered in the "candidate" column for account name of the ballot, or the name of the representative may be entered instead. When there are multiple representatives, the names of each respective representative shall be entered.</p>	<p>The revisions to this Article are proposed in accordance with applicable laws and regulations.</p>

After the Revision	Before the Revision	Explanation
<u>the proviso of Article 14-2, paragraph 1 of the Securities and Exchange Act, a by-election shall be held at the next shareholders meeting to fill the vacancy. When the independent directors are dismissed en masse, a special shareholders meeting shall be called within 60 days from the date of occurrence to hold a by-election to fill the vacancies.</u>		
<p>Article 6: A ballot is deemed as null and void if meeting any one of the following:</p> <ol style="list-style-type: none"> 1. Not a ballot provided by <u>a person with the right to convene the board of directors.</u> 2. A blank ballot is cast into the box. 3. A ballot bearing ambiguous wording or wording that has been tampered with. 4. Where the candidate whose name is entered in the ballot does not conform to the director candidate list, as a shareholder, is found inconsistent with the entries of name, shareholder account number in the Register (Roster) of Shareholders; where the candidate, as a non-shareholder, is found inconsistent in name, identity certificate code. 5. Other words or marks are entered in addition to the candidate's account name or shareholder account number (or identity card number) and the number of voting rights allotted. 6. Where the name of candidate entered is found the same as another shareholder's but there is no shareholder account code or identity certificate code 	<p>Article 6: A ballot is deemed as null and void if meeting any one of the following:</p> <ol style="list-style-type: none"> 1. Not a ballot provided by the board of directors. 2. A blank ballot is cast into the box. 3. A ballot bearing ambiguous wording or wording that has been tampered with. 4. Where the candidate, as a shareholder, is found inconsistent with the entries of name, shareholder account number in the Register (Roster) of Shareholders; where the candidate, as a non-shareholder, is found inconsistent in name, identity certificate code. 5. Other words or marks are entered in addition to the candidate's account name or shareholder account number (or identity card number) and the number of voting rights allotted. 6. Where the name of candidate entered is found the same as another shareholder's but there is no shareholder account code or identity certificate code available to identify. 	<p>The revisions to this Article are proposed in accordance with applicable laws and regulations.</p>

After the Revision	Before the Revision	Explanation
available to identify.—		
<p>Article 9:</p> <p>Elections of directors of the Company shall be conducted in accordance with the candidate nomination system and procedures set out in Article 192-1 of the Company Act. The Company shall review the qualifications, education, working experience, background, and the existence of any other matters set forth in Article 30 of the Company Act with respect to nominee directors and may not arbitrarily add requirements for documentation of other qualifications. It shall further provide the results of the review to shareholders for their reference, so that qualified directors and will be elected.—</p>	<p>Article 9:</p> <p>Elections of directors of the Company shall be conducted in accordance with the candidate nomination system and procedures set out in Article 192-1 of the Company Act. The Company shall review the qualifications, education, working experience, background, and the existence of any other matters set forth in Article 30 of the Company Act with respect to nominee directors and may not arbitrarily add requirements for documentation of other qualifications. It shall further provide the results of the review to shareholders for their reference, so that qualified directors and will be elected.</p>	<p>The revisions to this Article are proposed in accordance with applicable laws and regulations.</p>
<p>Article 12:</p> <p>This Procedure was enacted on Dec. 19, 2014, and any amendments hereto, shall be implemented after approval by a shareholders meeting.</p> <p>Amended on Sep. 13, 2016 for the first time.</p> <p>Amended on Jun. 12, 2018 for the second time.</p> <p><u>Amended on August 3rd, 2021 for the third time.</u></p>	<p>Article 12:</p> <p>This Procedure was enacted on Dec. 19, 2014, and any amendments hereto, shall be implemented after approval by a shareholders meeting.</p> <p>Amended on Sep. 13, 2016 for the first time.</p> <p>Amended on Jun. 12, 2018 for the second time.</p>	<p>Add the date of amendments.</p>

Attachment XII

Expert Opinion on a reasonable pricing of the private placement

I. Case Description

To introduce market partners and strengthen cooperative relationship between the two parties, EirGenix, Inc. (hereinafter referred to as EirGenix Company or the entrusted company) proposes a private placement of 55,000,000 shares and expects to conduct the first private placement of common shares in the year 2021. The management of the entrusted company states that the private placement price is expected to be no less than 50% of the reference price, and the private placement price is NTD91.5 per share. It is expected that the recipient of the private placement is HONG WEI INVESTMENT CO., LTD. (or its designated third-party company) (hereinafter referred to as HONG WEI Company), while the increase in the number of capital shares is estimated to be 55,000,000 common shares, and the total amount of additional funds is NTD5.0325 billion. The entrusted company currently issues 206,375,125 common shares. The convertible corporate bonds have been converted into common shares, and the number of unregistered shares is 35,025. In May 2021, it is estimated that 35,000,000 shares will be issued by cash capital increase along with the private placement of 55,000,000 shares, totaling 296,410,150 shares. After the private placement, HONG WEI Company will hold approximately 18.56% of the company's shares. The first private replacement increase in 2021 is based on April 19, 2021 as the reference pricing date.

According to the entrusted party's equity evaluation data, on April 19th, 2021, the closing price of EirGenix, Inc. is NT\$168.0 on the previous business day which is April 16th 2021. The average closing price from the first three business days to April 14th, 2021 is NT\$155.3. The average closing price for the first five business days to April 12, 2021 is NT\$154.8. The average closing price for the first 30 business days is NT\$105.1. EirGenix, Inc.'s securities market regulations related to the issuance of common shares issued by private replacement are pursuant to the content not analyzed in this opinion.

The management of the entrusted company states that during this year's private placement stock raising period, EirGenix, Inc. does not expect any other transaction events that will affect the number of shares. This opinion only assesses the rationality of the price of the EirGenix, Inc.'s private placement capital increase as follows.

II. The financial status of the target company as of December 31, 2020, is summarized as follows:

A. Balance Sheet as of December 31, 2020 (Summary)

Unit: NTD thousand

Accounting items	2020		2019	
	Amount	%	Amount	%

Cash and cash equivalents	908,346	24%	292,327	9%
Current financial assets as fair value through profit or loss	600	0%	0	0%
Current Financial assets at amortized cost	113,920	3%	0	0%
Net accounts receivable	226,622	6%	238,043	7%
Inventories	160,932	4%	163,968	5%
Prepayments	79,937	2%	346,268	10%
Other current assets	3,950	0%	7,651	0%
Total current assets	1,494,307	39%	1,048,257	31%
Non-current assets				
Non-current financial assets at fair value through other comprehensive income	5,956	0%	0	0%
Non-current financial assets at amortized cost	8,526	0%	11,158	0%
Property, plant, and equipment, net	1,851,850	48%	1,878,776	55%
Right-of-use asset	316,642	8%	333,043	10%
Intangible assets	33,129	1%	42,434	1%
Other non-current assets	124,805	4%	104,117	3%
Total non-current assets	2,340,908	61%	2,369,528	69%
Total assets	3,835,215	100%	3,417,785	100%
Current liabilities				
Current Contract liabilities	209,570	6%	160,333	5%
Accounts payable	41,161	1%	16,808	1%
Other payables	269,389	7%	178,800	5%
Other payables-related parties	4,069	0%	1,626	0%
Current Lease obligations	18,770	1%	16,861	0%
Other current liabilities	99,204	2%	105,897	3%
Total current liabilities	642,163	17%	480,325	14%
Non-current liabilities				
Non-current Contract liabilities	64,232	2%	115,995	4%
Bonds payable	291,985	7%	0	0%
Long term borrowings	626,081	16%	647,134	19%
Deferred income tax liabilities	366	0%	0	0%
Lease liabilities-non-current	304,771	8%	319,078	9%
Other non-current liabilities	0	0%	382	0%
Total non-current liabilities	1,287,435	33%	1,082,589	32%
Total liabilities	1,929,598	50%	1,562,914	46%
Equity attributable to owners of the parent company				
Equity				
Common stock	2,063,751	54%	1,693,041	49%
Capital reserve	2,813,974	73%	2,055,782	60%
Unappropriated Retained Earnings	-2,930,919	-76%	-1,889,249	-55%

Accumulated Deficit Member				
Other rights				
Reserve Of Exchange Differences On Translation Member	79	0%	0	0%
Reserve Of Gains And Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income Member	180	0%	0	0%
Other rights-other	-41,448	-1%	-4,703	0%
Total other equity interest	-41,189	-1%	-4,703	0%
Equity Attributable To Owners Of Parent Member	1,905,617	50%	1,854,871	54%
Total equity	1,905,617	50%	1,854,871	54%
Total liabilities and equity	3,835,215	100%	3,417,785	100%

Sources: 1. The 2020 and 2019 independent certified public accountant report and financial statements of the target company provided by the entrusted company..

Assets

1. Cash and bank deposits

As of December 31, 2020, cash and bank deposits accounted for 24% of total assets, which was an increase compared to the end of 2019, primarily due to the current cash capital increase and the issuance of corporate bonds.

2. Current Financial assets at fair value through profit or loss

December 31, 2020 mainly the evaluation of the option of convertible corporate bonds.

3. Current Financial assets at amortized cost

As of December 31, 2020, these accounted for 3% of total assets, which is an increase compared to the end of 2019, mainly due to the increase in fixed deposits and pledged deposits for cash capital increase during the current period.

4. Accounts receivable

As of December 31, 2020, these accounted for 6% of total assets, including contract assets and accounts receivable, which were accounts receivable of operating income for the current period.

5. Inventory

As of December 31, 2020, inventory accounted for 4% of total assets, which was a decrease compared to the end of 2019, mainly due to the increase in operating income during the current period and the relatively rapid inventory removal.

6. Prepayments and other current assets

Prepayments and other current assets accounted for 2% of total assets on December 31, 2020, which was a decrease compared to the end of 2019. This is mainly because a certain self-owned product enters the third phase of the clinical stage, and related consumables increase, so the prepaid supplies decrease due to faster inventory removal. Prepayments primarily consist of other accounts receivable, prepaid expenses, prepayments, etc.

7. Financial assets measured at fair value through other comprehensive gains and losses-non-

current

The balance as of December 31, 2020 was mainly investment in stocks of unlisted companies.

8. Non-current financial assets at cost

The balance on December 31, 2020 was mainly due to the pledge of time deposit.

9. Property, plant, and equipment

As on December 31, 2020, these accounted for 48% of total assets, a decrease compared with the end of 2019, mainly due to the current depreciation.

10. Right-of-use asset

As of December 31, 2020, it accounted for 8% of total assets, which was a decrease compared with the end of 2019, mainly due to the depreciation of the current period.

11. Intangible assets

As of December 31, 2020, these accounted for 1% of total assets, which was a decrease compared with the end of 2019, mainly due to the amortization and withdrawal in the current period.

12. Other non-current assets

As of December 31, 2020, these accounted for 4% of total assets, mainly due to in deposits, equipment prepayments and pledge deposits, etc.

Debt

13. Current Contract liabilities / accounts payable / other payables / other payables-related parties

As of December 31, 2020, these accounted for 14% of total assets, which were an increase compared with the end of 2019, mainly due to the increase in operating income during the current period and the increase in liabilities payable.

14. Lease obligations and other current liabilities

As of December 31, 2020, these liabilities accounted for 3% of total assets, mainly due to lease obligations for rent, temporary credits, receipts under custody.

15. Bonds payable

As of December 31, 2020, bonds accounted for 7% of total assets, mainly due to convertible corporate bonds issued.

16. Long-term borrowings

As of December 31, 2020, these loans accounted for 16% of total assets, which was a decrease compared with the end of 2019, mainly due to repayment due in the current period.

17. Deferred income tax liabilities/lease liabilities-non-current

As of December 31, 2020, these liabilities accounted for 8% of total assets, a decrease from the end of 2019, mainly due to the periodical payment of lease obligations.

Shareholders' equity

18. Shareholders' equity is the total of share capital, capital reserves, retained earnings, unrealized gains and losses of financial assets, and conversion differences in financial statements of foreign operating institutions.

B. Income Statement in 2020 (Summary)

Unit: NTD: thousand

Subject	2020	2019
Operating Revenue	1,071,838	476,085
Operating costs	321,171	221,418
Gross margin	750,667	254,667
Operating expenses	1,736,671	1,102,338
Business interest	- 986,004	- 847,671
Non-operating income and expenditure	-55,319	-13,254
Net profit before tax	- 1,041,323	- 860,925
Income tax expense	347	-
Net profit after tax	-1,041,670	-860,925

Sources: 1. The 2020 and 2019 independent certified public accountant report and financial statements of the target company provided by the entrusted company.

19. Operating revenue and gross profit

In 2020, due to the business growth of CDMO and the recognition of customer's royalty income of the target company, the target company increases its revenue and gross profit from new contract signing and milestone payments as compared with the previous period.

20. Operating expenses

Expenses primarily include salary and other personnel expenses, office management expenses and R&D expenses. In 2020, a certain R&D product entered the third phase of clinical trial, while other products continued to be developed, and operating revenue, and operating expenses rose relatively.

21. Non-operating revenue and expenditure

Mainly interest income, exchange gains and losses, other income, etc.

C. Target company's profile

The target company was established on December 21, 2012 in the Republic of China as a listed company. In April 2013, EirGenix, Inc. undertook all the key technologies of the

pharmaceutical pilot technology factory of the biotechnology development center of the consortium, and assimilated its complete core synergy and excellent quality technical staff. The experience accumulated in the past is the starting point, enabling EirGenix to quickly gain a firm foothold. With the hard work of the strong technical and management team composed of the general manager and professional talents recruited at home and abroad, EirGenix's CDMO business has been developed in just four years. It grew by more than 28 times and reached a balance of profit and loss in 2016. The steady growth of the business represents the trust of domestic and foreign customers in EirGenix's technology and operations. The team uses professional experience and technology to help customers go faster and further on the journey of biotechnology drug development.

Drug development

EirGenix, Inc. is currently developing a total of 7 drugs, which can be divided into three main areas, of which 4 are biosimilar drugs for the treatment of breast cancer HER2 gene mutation, 2 are biologic drugs that inhibit tumor angiogenesis, and 1 is a vaccine carrier protein.

(Source: the official website of the entrusted company and the target company)

Directors and supervisors information

Source: An entrusted company to provide information on the reporting date April 21, 2021

	<u>Title</u>	<u>Name</u>	<u>Legal Corporate Representative</u>	<u>Number of shares held (shares)</u>
1	Chairman	Chung-Hur Lee	Augusta Inc.	874,141
2	Director	Cheng-Yu Cheng	Formosa Laboratories, Inc.	17,225,219
3	Director	Hsiu-Hui Chen	Development Center for Biotechnology	5,440,834
4	Director	Jing-Jer Lin	National Development Fund, Executive Yuan	13,563,887
5	Director	Lee-Cheng Liu		1,682,769
6	Director	Wei-Hung Chang	Yao-Hwa Glass Co., Ltd, Management Commission	11,602,541
7	Director	I-Ta Lu	Taiwania Capital Buffalo II Bioventures, LP	9,705,056
8	Independent			
	Director	Ming-Shen Chen		0
9	Independent			
	Director	Fu-Shiow Yin		0
10	Independent			
	Director	Ming-Thaur Chang		0

III.Description of evaluation method

There are three primary evaluation methods of equity fair value

- Asset-based method: The net asset value of the company being assessed is the equity value. The fair market value of each asset and liability is evaluated item by item on the evaluation base date, and then the market price of total assets is subtracted from the market

price of total liabilities.

- Market-based method: It is assumed that the fair value of the target company is determined by comparison of profits of companies operating similar to the market or comparison of similar trading transactions.
- Income-based method: Based on the target company's future earnings cash flow as a measurement basis, the cash flow available for future operations is estimated through a reasonable estimated financial forecast, and the cash flow is discounted at a discount rate that can reasonably express the risk on the evaluation base date.
- The evaluation method should be adjusted by considering factors such as the company's industrial characteristics, stock liquidity, future profitability, and other factors.

Based on the equity price evaluation information of the entrusted company, the equity price is evaluated by the market-based method and the income-based method. The current operating conditions of the target company and the private placement capital increase are based on the evaluation base date of April 19, 2021, as the reference pricing date, and on December 31, 2020, the target company's audited statements by accountants as the basis, and the market law is comparable. The listed company method and the income-based method use the discounted present value of future cash flows to analyze the value of equity. In addition, because the target company is a listed company, the stock price method is used to calculate and analyze, and the market price of the target company is used to calculate the private placement price. The price calculation is explained as follows.

IV. Explanation of calculation of equity price

A. Market-based Method

In the first quarter of 2021, because the target company lost money in 2020 and 2019, based on the equity price information of the entrusted company on March 31, 2021, the equity value is analyzed by the market-based method of stock price and net value, and the income method is used for the estimated five-year free cash flow annuity net profit, using the price-to-earnings ratio method to analyze the equity value is as follows:

(A) The price-to-net value ratio method

Table1: The price-to-net value ratio method

Unit: NTD/Share

Item/ Content (2020)	Average same business (A)	Target company's net value per share at the end of 2020 and the end of the first quarter of 2021 (B)	Price per stock market of the target company at the end of the first quarter of 2021 (C=A*B)	Liquidity reduction of private placement (D)	Target company adjusted price per share (E=C*(1- D))
Price-to-net value ratio (Note 1)	6.93	9.234	64.02	20%	51.21
Price-to-net	6.93	25.121	174.16	20%	139.33

value ratio (Note 2)					
Price-to-net value ratio (Note 3)	6.93	24.382	169.04	20%	135.23
Price-to-net ratio (Note 4)	6.93	20.252	140.41	20%	112.33

Note

1. Data source: The entrusted company permits the target company's the net value per share from the balance sheet in 2020 target company's independent certified public accountant report and financial statements.
2. The entrusted company permits the target company's the net value per share from the balance sheet in 2020 target company's independent certified public accountant report and financial statements plus the expected cash capital increase and the execution of the private placement fund plan, divided by the expected number of shares after the private placement.
3. The net value per share calculated by the entrusted company provides the net value of the target company's self-closing statement at the end of March 2021 plus the expected cash capital increase and the execution of the private placement fund plan, divided by the expected number of shares after the private placement.
4. The net value per share calculated by the entrusted company provides the net value of the target company's self-closing statement at the end of March 2021 plus the estimated cash capital increase, divided by the estimated number of capital increase shares to calculate the net value per share.
5. Comparable companies in the industry are listed on the counter company, which is a pharmaceutical development peer calculation. Since the target company will lose money in the first quarter of 2021, 2020 and 2019, it is prudent to be financially stable and similar in size to the target company. The company is the target company for comparison in the industry. As for Industry Information, refer to Appendix V for details.
6. The stock price, price-to-earnings ratio, and price-to-net value ratio of listed companies come from statistical reports published by the stock exchanges and OTC of the securities markets.
7. The independent certified public accountant report and financial statements for the fourth quarter of 2020 of various companies are obtained from the MOPS of the securities market stock exchanges.
8. The private placement stocks that the target company is expected to issue are subject to restrictions such as not being sold within three years from the delivery date. The market liquidity of private placement is worse than common stocks, and its value is listed as a discount due to its lack of liquidity. It is proposed that the value is adjusted for lack of liquidity at a discount of 20%. According to the International Private Equity and Venture Capital Valuation Guidelines developed by AFIC, BVCA and EVCA, all relevant factors shall be taken into consideration when concluding that there is no market liquidity discount. Generally speaking, the discount range for non-market liquidity is between 10% and 30%.

(B) Price-to-earnings ratio method

Table 2: Price-to-earnings ratio method

Unit: New Taiwan Dollar: Dollar/Share

Item/Content (annuity)	Average same business (A)	Target company's net value per share at the end of 2020 and the end of the first quarter of 2021 (B)	Price per stock market of the target company at the end of the first quarter of 2021 ($C=A*B$)	Liquidity reduction of private placement (D)	Target company adjusted price per share ($E=C*(1-D)$)
Price-to-earnings ratio	26.440	2.306	60.98	20%	48.79

Note

1. Data source: The net profit per share is calculated by the annuity method of net profit per share based on the income method (the number of shares is 296,410 thousand shares).
2. Comparable companies in the industry are listed on the counter company, which is a pharmaceutical development peer calculation. Since the target company will lose money in the first quarter of 2020, 2019, it is prudent to be financially stable and similar in size to the target company. The company is the target company for comparison in the industry. As for Industry Information, refer to Appendix V for details.
3. The stock price, price-to-earnings ratio, and price-to-net value ratio of listed companies come from statistical reports published by the stock exchanges and TPEx of the securities markets.
4. The independent certified public accountant report and financial statements for the fourth quarter of 2020 of various companies are obtained from the MOPS of the securities market stock exchanges.
5. The private placement stocks that the target company is expected to issue are subject to restrictions such as not being sold within three years from the delivery date. The market liquidity of private placement is worse than ordinary common stocks, and its value is listed as a discount due to its lack of circulation. It is proposed that the value is adjusted for lack of liquidity at a discount of 20%. According to the International Private Equity and Venture Capital Valuation Guidelines developed by AFIC, BVCA and EVCA, all relevant factors shall be taken into consideration when concluding that there is no market liquidity discount. Generally speaking, the discount range for non-market liquidity is between 10% and 30%.

After checking and calculating the aforementioned data, the value of each share calculated by the price-to-net value ratio method of market-based method is NTD51.21-139.33, considering the development plan and status of the target company, the average stock price calculated by the end of 2020 and the end of the first quarter of 2021 based on the estimated number of shares in circulation after the cash capital increase and private placement is used as the net price of the stock price of NTD128.96. The value per share of the company under the P/E ratio method is NT\$48.79.

(C) Stock price averaging method

Because the target company itself is a listed company, it is proposed to calculate and analyze the equity value based on the target company's recent stock price as follows:

Table 3 Stock price averaging method

Unit: New Taiwan Dollar /Share

Date	Simple arithmetic average of common stock closing prices (A)	Liquidity reduction of private placement (D)	Target company adjusted price per share ($E=C*(1-D)$)
Thirty business days before April 19, 2021	105.06	20%	84.05
Sixty business days before April 19, 2021	76.48	20%	61.19

Note

1. The stock price, price-to-earnings ratio, and price-to-net value ratio of listed companies come from statistical reports published by the stock exchanges and TPEx of the securities markets.
2. The private placement stocks that the target company is expected to issue are subject to restrictions such as not being sold within three years from the delivery date. The market liquidity of private placement is worse than ordinary common stocks, and its value is listed as a discount due to its lack of circulation. It is proposed that the value is adjusted for lack of liquidity at a discount of 20%. According to the International Private Equity and Venture Capital Valuation Guidelines developed by AFIC, BVCA and EVCA, all relevant factors shall be taken into consideration when concluding that there is no market liquidity discount. Generally speaking, the discount range for non-market liquidity is between 10% and 30%.

After checking and calculating the aforementioned data, the simple arithmetic average value of each share of the market-based method target company's closing price is NT\$61.19-84.05. Taking into account the recent stock market price trend of the target company, the average price of the previous 30 business days is expected to be included in the average price of NTD 84.05.

B.Income-based method

Based on the entrusted company to provide the target company's equity price information for the first quarter of 2021, the rationality analysis of the value evaluation using the income-based method of stock price and net value analysis is as follows:

1. Discount rate estimation

It is measured based on the principal's estimated future cash flow of the target company's earnings, and discounted at the shareholders' possible capital discount rate. The calculation of the discount rate formula is as the calculation of the capital cost rate in appendix VI.

2. The discounted value of free cash flow

The target company's free cash flow after tax is based on the target company's 6-year profit and loss forecast provided by the entrusted company, plus the assumptions of the target company's depreciation and amortization and working capital. The calculation is shown in Appendix VI.

3. Liquidity reduction of private placement stocks

The private placement stocks that the target company is expected to issue are subject to restrictions such as not being sold within three years from the delivery date. The market liquidity of private placement is worse than common stocks, and its value is listed as a discount due to its lack of circulation. It is proposed that the value is adjusted for lack of liquidity at a discount of 20%. According to the International Private Equity and Venture Capital Valuation Guidelines developed by AFIC, BVCA and EVCA, all relevant factors shall be taken into consideration when concluding that there is no market liquidity discount. Generally speaking, the discount range for non-market liquidity is between 10% and 30%.

Table 4 Income basis method

Unit: New Taiwan Dollar: Thousand Dollar / Thousand Shares

Discount Rate	12.00%
Total discounted value (pre-adjustment corporate value)	2,810,801
Total discounted value (adjusted equity value)	5,197,869
Number of shares of the target company	296,410
Adjusted price per share (Taiwan Dollar: Dollar)	17.54
Liquidity reduction of private placement	20%
Adjusted price per share (Taiwan Dollar: Dollar)	14.03

Note

1. Data source: The target company's estimated profit and loss statement from 2021 to 2026 is provided by the principal..
- 2 The adjusted equity value is the discounted present value. After considering the cash capital increase and private placement of the target company, it is estimated that the loan and booked cash adjustments will be made at the end of the first quarter of 2021.
- 3.The number of shares is calculated based on the 296,410,000 shares outstanding after the target company's estimated cash capital increase and 55,000,000 private placement shares.

After checking and calculating the aforementioned data, the price per share of the income-based method is NTD14.03. As the price of the income-based method is highly discrete from other prices, it is proposed to not adopt the income-based method.

V. Summary of equity prices

A. Instructions for calculating the price of private placement

(A). TWSE listed or TPEx listed company use the following two benchmarks to calculate the higher price:

- (1) The simple average closing price of the common shares for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction.
- (2) The simple average closing price of the common shares for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction.

(B) The tentative private placement reference price is calculated as shown in Table 5.

Table 5 Tentative Private Placement Reference Price

Unit: New Taiwan Dollar: Dollar /Share

Date	Common stock closing price	Simple arithmetic average (Note 2)
Pricing Date April 19, 2021		
(1) One business day before the pricing day	168.0	168.0
Three business days before the pricing date	145.0	155.3
Five business days before the pricing date	160.0	154.8
(2) Thirty business days before the pricing date		105.1
(3) Provisional private placement reference price (the higher of the two)		168.0

Note

1. Data source: The closing price of the target company's stock price is provided by the principal.
2. The principal stated that the target company currently has no ex-rights for gratuitous allotment, dividends, and capital reductions that need to be adjusted.

The tentative private placement reference price of the target company's private placement tentative pricing date on April 19, 2021 is NTD168.0.

B. Summary of equity prices

The price calculated by the aforementioned methods is summarized in Table 6, considering the current operating conditions of the target company, and after discussion with the management of the entrusted company:

Table 6 Summary of Equity Price

Unit: New Taiwan Dollar: Dollar /Share

Item/Content	Adjusted price per share of target company
Price-to-net ratio	128.96
Price-to-earnings ratio	48.79
Stock price method	84.05
Total	261.80
Average	87.27

After checking and calculating the aforementioned data, the entrusted company is expected to increase the capital by private placement of 55,000,000 shares at NTD 91.5, and the price is within the aforementioned price range and is not lower than the average. The entrusted company expects that the private placement price is not less than 50% of the tentative private placement reference price, and the private placement price is NTD 91.5 that is 54% of the tentative private placement reference price of NTD168.0, that is, no less than 50%, which is not unreasonable.

Champion United Accounting Firm

Accountant: Lin Xiulian

April 21st, 2021

Appendix

1. Basic assumptions and reporting restrictions
2. Introduction to Independent Experts
3. Declaration of Independence
4. Data Source
5. Industry Information
6. Description of discount rate and income method calculation

1. Basic assumptions and restrictions on the use of submissions

Basic assumptions

- There will be no major changes in domestic and foreign politics, regulations and overall economy since the issuance of the opinion report.
- The provisions of domestic and foreign tax laws have not changed significantly since the issuance of the opinion report.
- The relevant industries of the target company have no major changes since the issuance of the opinion report.

Restrictions on the use of submissions

- This opinion is not suitable as the sole basis for price decision. The final price of equity still needs to consider other factors outside the scope of this opinion that may affect the transaction.
- To the fullest extent permitted by law, the firm will not be liable for any third party for this report, information or explanations related to this report. Accordingly, within the scope permitted by law, any third party takes or fails to take the consequences of actions taken or not taken in any form in accordance with this report, related information or explanations of this report, regardless of contractual relationship or tort (including but not limited to those caused by negligence) or other actions, the company does not bear any responsibility.
- When the firm executes the rationality opinion work, it analyzes the equity price evaluation data provided by the entrusted company and various information and data obtained from public sources. However, the firm does not make any assumptions about the financial statement data or assumptions. The correctness, existence or completeness is verified or audited, and no opinion is expressed. If the information provided by the client and the target company is false, which causes losses to other parties or causes litigation, the firm does not bear such responsibilities, and hereby declares.
- The operation of the reasonableness opinion is not an accurate check calculation in nature. In most cases, its conclusion will inevitably involve subjective and professional judgment.
- The actual price of the transaction varies depending on the subjective and objective factors at the time, such as control rights, competitive conditions, financial capabilities, and negotiation skills between the two parties.

2. Introduction to Independent Experts

Name: Lin Xiulian

Professional qualifications

Accountant of the Republic of China

Passed the American Accountant Examination

Corporate Appraiser

Real estate appraiser

Land Administration Agent

Education

Drexel University MBA, Pennsylvania, USA

Bachelor of Accounting, National Taiwan University

Experience

Deloitte Touche Tohmatsu Limited("DTTL") Accounting Firm Partnership Accountant

R&K Accounting Firm Accounting Firm Partnership Accountant

Current job

Champion United Accounting Firm, Partner Accountant

Director of Champion Real Estate Appraisal Firm

Director of Chengxin Land Political Office

3. Declaration of Independence

I am entrusted to provide an expert opinion on the reasonableness of the private placement price of the entrusted company.

To carry out the business, I hereby declare that I do not have the following circumstances:

1. I or my spouse is currently employed by the above-mentioned company or affiliated company as a regular job and receiving a fixed salary.
2. I or my spouse who had worked as an employee of the above-mentioned company or affiliated company, and had been dismissed for less than 2 years.
3. The company in which I or my spouse works and the above-mentioned company or its affiliated companies are mutually related parties.
4. Have a spouse or relative relationship with the person in charge or manager of the above-mentioned company or its affiliated company.
5. I have signed a contract with the above-mentioned company or have public expense.
6. Violation of other circumstances that may affect my objectivity and independence.

4. Data Source:

- The firm conducts analysis based on the equity price evaluation information provided by the target company and the entrusted company and the information obtained from public sources. The analysis conclusion is based on the premise that the above information is complete and has no major errors.
- The information provided by the target company primarily includes:
 - Independent Certified Public Accountant Report and Financial Statements of the target company at the end of December 2020 and 2019
 - The target company's equity price calculation information on March 31, 2021
 - Target company 2021-2026 financial forecast information
 - Entrusted company board information
- Entrust the discussion with the management of the company
 - April 12, 2021 -April 21, 2021, discuss and clarify relevant information by telephone and email with the chief financial officer of the entrusted company and senior manager Wen.

5. Industry Information

Unit: New Taiwan Dollar: Thousand

Item	Total Assets	Total Liabilities	Total equity	Equity attributable to owners of the parent company	Operating income	Net profit after tax attributable to the parent company	Net Value Ration	P/E ratio
3176 Medigen	6,152,426	1,652,956	4,499,470	1,815,418	615,541	-13,766	5.03	N/A
4174 OBI	5,339,850	502,091	4,837,759	4,229,022	140,886	-1,377,935	7.06	N/A
4147 TaiMed	5,196,323	1,780,445	3,415,878	3,415,878	722,485	-183,304	5.74	NA
6541 Tanvex	4,372,725	1,752,010	2,620,715	2,620,715	300	-2,104,236	10.58	NA
4726 Mycenax	1,752,553	540,886	1,211,667	1,211,667	665,341	30,948	3.65	143.75
6472 Bora	7,004,179	4,539,415	2,464,764	2,464,764	1,799,570	578,426	4.34	18.36
6589 EirGenix	3,835,215	1,929,598	1,905,617	1,905,617	1,071,838	-1,041,670	12.13	N/A
Total							48.53	
Average							6.93	

Note

1. The industry's financial information for 2020.
2. The stock price, price-to-earnings ratio and price-to-net value ratio of listed companies come from statistical reports published by the stock exchanges and TPEx of the securities markets.
3. The financial statements for accountant audit reports of various companies in 2020 are obtained from the MOPS of the securities market stock exchanges.
4. Since the industry is a drug research and development company, most of them are still at a loss. It is prudent to use 6472 Bora, 4128 CTI and 4105 TTY.

Calculating the price-to-earnings ratio method in Table 2 with an average ratio of 26.44, Yongxin's price-to-earnings ratio is highly discrete from other peers and is not included.

6. Description of discount rate and income method calculation

6.1 Calculation of the target company's capital risk discount rate

Discount rate analysis factor	Value (%)	Source basis
Risk-free rate	0.7005	The weighted yield rate of the 20-year government bond auction; Data source: Central Bank website
Securities risk premium	9.63	$(10.03\% - 0.7005\%) \times 1.0322$; 10.03% is the average share price return rate of Taiwan weighted stock index, 1.0322 is the Beta median of the comparison company
Scale risk	3.34%	D&P Handbook
Equity discount rate	13.67%	$0.7005\% + 9.63\% + 3.34\% = 13.67\%$
Weighted capital discount rate	12%	$13.67\% \times 88\% + 1.8\% \times 12\% \times (1 - 20\%) = 12.2\% \Rightarrow 12\%$

1. Weighted Average Cost of Capital (WACC)

$$WACC = D/A \times R_d \times (1 - T) + E/A \times R_e$$

R_d : Interest rate of interest-bearing liabilities

D/A : Interest-bearing debt ratio

R_e : Shareholder demand rate of return

E/A : Equity ratio is the ratio of shareholders' equity to the total invested capital calculated at market price

T : tax rate

Based on the principal's management estimates and the inter-bank interest-bearing debt ratio in 2020, it is assumed that the interest-bearing debt of long-term perpetual operation accounts for 12% and the interest-bearing debt rate is 1.8%.

2. Capital asset pricing model formula

The formula for the Expected Return of the stock portfolio is as follows:

$$R_e = R_f + \beta_a \times (R_M - R_F)$$

Among them, R_F (Risk free rate) is the risk-free rate of return, the pure time value of money;

β_a is the Beta coefficient of the security,

R_M is the expected market return (Expected Market Return),

$R_M - R_F$ is Equity Market Premium.

R_F : Based on the 20-year government bond yield

R_M : Taiwan weighted stock price index [1967/01/07~2021/03/31] Annualized rate of return on stock market

β_a : The company uses similar industries as the source of β_a , the median of peer companies (Source: TEJ, Yahoo and other websites)

6.2 Calculation of the discounted value of the target company's free cash flow

Unit: New Taiwan Dollar: Thousand dollar /thousand shares

Item/year	2021	2022	2023	2024	2025	2026
Free cash flow	- 670,020	- 144,364	- 346,780	- 19,2021	1,253,332	1,379,815
Discount Rate	12%	12%	12%	12%	12%	12%
Discount factor	0.8929	0.7972	0.7118	0.6355	0.5674	0.5066
Discounted value	-598,232	- 115,086	- 246,831	- 12,144	711,174	699,057
Total discounted value						437,937
Plus: final value						2,372,863
Total enterprise value						2,810,801
Adjusted equity value						5,197,869
Number of shares						296,410
Value per share (dollar)						17.54
Uncirculated discount						20%
Value per share after uncirculated discount (dollar)						14.03

Note

1. Source: The target company's estimated profit and loss statement from 2021 to 2026 is provided by the principal. 2021 refers to 2021.4.1-2022.3.31, and so on in subsequent years.
2. The number of shares is calculated based on the 296,410 thousand shares outstanding after the target company's expected cash capital increase and private placement of 55,000,000 shares.
3. The private placement stocks expected to be issued by the target company are restricted from being sold within three years from the delivery date. The market liquidity of private placement is lower than that of common stocks, and its value is listed due to its lack of circulation at a discount. Proposed value to lack the liquidity adjustment discount is 20%. According to the International Private Equity and Venture Capital Valuation Guidelines developed by AFIC, BVCA, and EVCA, when judging that there is no market liquidity discount environment, considering all relevant factors. Generally speaking, the discount range for non-market liquidity is between 10% and 30%.
4. The final value is the estimated book value of the real estate and equipment at the end of 2026, discounted to the evaluation base date.
5. The adjusted equity value takes into account the cash and interest-bearing liabilities of the target company in the first quarter of 2021.